{"NCT01713582":{"publications":["26976114","33371192"],"projects":["3R01CA124633-11A1S1","5R01CA176745-09"],"title":"A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)","recruitment_status":"Completed","last_update_posted":"January 26, 2021"},"NCT02259114":{"publications":["26976114","27509377","28484033","33371192"],"projects":["3R01CA124633-11A1S1","5R01CA176745-09"],"title":"A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)","recruitment_status":"Completed","last_update_posted":"January 26, 2021"},"NCT02296476":{"publications":["26976114","33371192"],"projects":["3R01CA124633-11A1S1","5R01CA176745-09"],"title":"A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)","recruitment_status":"Terminated","last_update_posted":"January 26, 2021"},"NCT01587703":{"publications":["26976114","27509377","28484033"],"projects":["3R01CA124633-11A1S1"],"title":"A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers","recruitment_status":"Completed","last_update_posted":"March 16, 2020"},"NCT01987362":{"publications":["26976114","27509377","28484033","33371192"],"projects":["3R01CA124633-11A1S1","5R01CA176745-09"],"title":"A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies","recruitment_status":"Completed","last_update_posted":"January 5, 2018"},"NCT02158858":{"publications":["26976114"],"projects":["3R01CA124633-11A1S1"],"title":"A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis","recruitment_status":"Recruiting","last_update_posted":"August 25, 2021"},"NCT02431260":{"publications":["27509377","28484033"],"projects":["3R01CA124633-11A1S1"],"title":"An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies","recruitment_status":"Terminated","last_update_posted":"June 14, 2019"},"NCT02307240":{"publications":["27509377"],"projects":["3R01CA124633-11A1S1"],"title":"Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors","recruitment_status":"Completed","last_update_posted":"September 3, 2019"},"NCT02427451":{"publications":["28111464"],"projects":["3R01CA205967-03S2"],"title":"Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia","recruitment_status":"Active, not recruiting","last_update_posted":"November 6, 2019"},"NCT03098160":{"publications":["29485185"],"projects":["3R01CA187532-03S1"],"title":"Immunotherapy Study of Evofosfamide in Combination With Ipilimumab","recruitment_status":"Unknown","last_update_posted":"October 30, 2017"},"NCT02744287":{"publications":["29590011","32916097"],"projects":["3R01CA163915-07S1","1U54CA244438-01"],"title":"Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors","recruitment_status":"Recruiting","last_update_posted":"April 26, 2021"},"NCT02743611":{"publications":["29590011"],"projects":["3R01CA163915-07S1"],"title":"Safety &amp; Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma","recruitment_status":"Active, not recruiting","last_update_posted":"April 27, 2020"},"NCT01896479":{"publications":["29693796"],"projects":["5UM1CA228823-03"],"title":"A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer (EXAMINER)","recruitment_status":"Active, not recruiting","last_update_posted":"July 26, 2021"},"NCT01709435":{"publications":["29693796"],"projects":["5UM1CA228823-03"],"title":"Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors","recruitment_status":"Completed","last_update_posted":"April 7, 2020"},"NCT02867592":{"publications":["29693796"],"projects":["5UM1CA228823-03"],"title":"Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors","recruitment_status":"Active, not recruiting","last_update_posted":"September 8, 2021"},"NCT01780662":{"publications":["30122620"],"projects":["5UM1CA228823-03"],"title":"Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma","recruitment_status":"Active, not recruiting","last_update_posted":"June 16, 2021"},"NCT02164838":{"publications":["30394521"],"projects":["5UM1CA228823-03"],"title":"VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors","recruitment_status":"Completed","last_update_posted":"January 29, 2018"},"NCT01657682":{"publications":["30541869"],"projects":["3R01CA182543-05S2"],"title":"A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations","recruitment_status":"Completed","last_update_posted":"July 20, 2020"},"NCT02639026":{"publications":["30660727"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers","recruitment_status":"Active, not recruiting","last_update_posted":"March 9, 2021"},"NCT02648282":{"publications":["30660727"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"August 9, 2021"},"NCT03245541":{"publications":["30660727"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer","recruitment_status":"Recruiting","last_update_posted":"August 9, 2021"},"NCT03190265":{"publications":["30660727"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer","recruitment_status":"Recruiting","last_update_posted":"August 20, 2021"},"NCT02451982":{"publications":["30660727"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab and Urelumab Trial for Surgically Resectable Pancreatic Cancer","recruitment_status":"Recruiting","last_update_posted":"March 22, 2021"},"NCT03153410":{"publications":["30660727"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas","recruitment_status":"Active, not recruiting","last_update_posted":"August 19, 2021"},"NCT03006302":{"publications":["30660727"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer","recruitment_status":"Recruiting","last_update_posted":"August 20, 2021"},"NCT03214250":{"publications":["30660727","31158393","33158848"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01","1U54CA232568-01"],"title":"Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma","recruitment_status":"Active, not recruiting","last_update_posted":"July 30, 2021"},"NCT02758587":{"publications":["30660727"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)","recruitment_status":"Recruiting","last_update_posted":"March 19, 2018"},"NCT02546531":{"publications":["30660727","34025067"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01","1U54CA224083-01"],"title":"Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer","recruitment_status":"Completed","last_update_posted":"July 20, 2021"},"NCT03481920":{"publications":["30660727"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer","recruitment_status":"Terminated","last_update_posted":"August 22, 2019"},"NCT03193190":{"publications":["30660727","31158393"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)","recruitment_status":"Active, not recruiting","last_update_posted":"August 5, 2021"},"NCT03634332":{"publications":["30660727"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC","recruitment_status":"Unknown","last_update_posted":"May 7, 2019"},"NCT02777710":{"publications":["30660727"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers (MEDIPLEX)","recruitment_status":"Completed","last_update_posted":"September 5, 2021"},"NCT02526017":{"publications":["30660727"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)","recruitment_status":"Completed","last_update_posted":"July 31, 2020"},"NCT02436668":{"publications":["30660727"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)","recruitment_status":"Completed","last_update_posted":"December 30, 2020"},"NCT03496662":{"publications":["30660727"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)","recruitment_status":"Recruiting","last_update_posted":"July 23, 2021"},"NCT03404960":{"publications":["30660727","31158393"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (Parpvax)","recruitment_status":"Recruiting","last_update_posted":"June 10, 2021"},"NCT00798213":{"publications":["30665374"],"projects":["1U24CA224067-01"],"title":"SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)","recruitment_status":"Terminated","last_update_posted":"February 4, 2015"},"NCT00937937":{"publications":["30665374"],"projects":["1U24CA224067-01"],"title":"Dinaciclib in Treating Patients With Stage IV Melanoma","recruitment_status":"Active, not recruiting","last_update_posted":"August 5, 2021"},"NCT03253679":{"publications":["30665374"],"projects":["1U24CA224067-01"],"title":"AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification","recruitment_status":"Suspended\n                  \n      <!--","last_update_posted":"August 16, 2021"},"NCT03478397":{"publications":["30808379","32032940","33264086"],"projects":["1R01CA218306-01"],"title":"Evaluation of a mHealth Intervention to Increase Adherence to Triage of Self-collected HPV+ Women (ATICA Project) (ATICA)","recruitment_status":"Completed","last_update_posted":"April 6, 2021"},"NCT01130077":{"publications":["30810873"],"projects":["2UM1CA081457-21"],"title":"A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas","recruitment_status":"Active, not recruiting","last_update_posted":"August 10, 2021"},"NCT02358031":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)","recruitment_status":"Active, not recruiting","last_update_posted":"October 23, 2020"},"NCT02741570":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 651)","recruitment_status":"Active, not recruiting","last_update_posted":"April 19, 2021"},"NCT00771641":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck","recruitment_status":"Completed","last_update_posted":"January 24, 2014"},"NCT03383094":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer","recruitment_status":"Recruiting","last_update_posted":"February 8, 2021"},"NCT03317327":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors (REPORT)","recruitment_status":"Recruiting","last_update_posted":"September 30, 2019"},"NCT03546582":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma (KEYSTROKE)","recruitment_status":"Recruiting","last_update_posted":"August 3, 2021"},"NCT02296684":{"publications":["30814108","32665297"],"projects":["1R33CA225291-01","1U01DE028227-01","3U24CA237719-02S1"],"title":"Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma","recruitment_status":"Active, not recruiting","last_update_posted":"August 30, 2021"},"NCT03051906":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer (DUCRO-HN)","recruitment_status":"Not yet recruiting","last_update_posted":"November 22, 2017"},"NCT02999087":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) (REACH)","recruitment_status":"Active, not recruiting","last_update_posted":"November 4, 2020"},"NCT02764593":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"August 3, 2021"},"NCT03247712":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Neoadjuvant Immunoradiotherapy in Head &amp; Neck Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"May 20, 2021"},"NCT03673735":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC (ADHERE)","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"May 10, 2021"},"NCT03529422":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN","recruitment_status":"Recruiting","last_update_posted":"May 11, 2021"},"NCT03426657":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC","recruitment_status":"Recruiting","last_update_posted":"June 11, 2021"},"NCT03509012":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)","recruitment_status":"Active, not recruiting","last_update_posted":"July 21, 2021"},"NCT03539198":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"April 5, 2021"},"NCT03085719":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN","recruitment_status":"Recruiting","last_update_posted":"November 13, 2020"},"NCT03283605":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas","recruitment_status":"Recruiting","last_update_posted":"May 27, 2021"},"NCT03313804":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Priming Immunotherapy in Advanced Disease With Radiation","recruitment_status":"Recruiting","last_update_posted":"June 14, 2021"},"NCT02777385":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer","recruitment_status":"Recruiting","last_update_posted":"April 6, 2021"},"NCT03349710":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer","recruitment_status":"Completed","last_update_posted":"August 9, 2021"},"NCT02892201":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Pembrolizumab in HNSCC With Residual Disease After Radiation","recruitment_status":"Active, not recruiting","last_update_posted":"July 15, 2021"},"NCT02841748":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study","recruitment_status":"Recruiting","last_update_posted":"January 7, 2021"},"NCT03040999":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)","recruitment_status":"Active, not recruiting","last_update_posted":"April 19, 2021"},"NCT02952586":{"publications":["30814108","33368875"],"projects":["1R33CA225291-01","1U01DE028227-01","1U01DE029188-01"],"title":"Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)","recruitment_status":"Terminated","last_update_posted":"September 22, 2021"},"NCT03452137":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck","recruitment_status":"Recruiting","last_update_posted":"August 5, 2021"},"NCT01302834":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"February 23, 2021"},"NCT01040832":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Na&#239;ve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","recruitment_status":"Completed","last_update_posted":"January 30, 2017"},"NCT01334177":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck","recruitment_status":"Completed","last_update_posted":"March 5, 2015"},"NCT01360827":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck","recruitment_status":"Terminated","last_update_posted":"June 17, 2014"},"NCT01468896":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery","recruitment_status":"Active, not recruiting","last_update_posted":"March 22, 2021"},"NCT01836029":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","recruitment_status":"Completed","last_update_posted":"October 29, 2019"},"NCT01935921":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"June 15, 2021"},"NCT02110082":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer","recruitment_status":"Completed","last_update_posted":"April 19, 2017"},"NCT02124850":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab","recruitment_status":"Terminated","last_update_posted":"October 25, 2019"},"NCT02633800":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )","recruitment_status":"Terminated","last_update_posted":"January 7, 2019"},"NCT02643550":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","recruitment_status":"Active, not recruiting","last_update_posted":"February 9, 2021"},"NCT02938273":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)","recruitment_status":"Completed","last_update_posted":"December 11, 2019"},"NCT03082534":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head &amp; Neck Squamous Cell Carcinoma","recruitment_status":"Recruiting","last_update_posted":"March 11, 2021"},"NCT03370276":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Cetuximab &amp; Nivolumab in Patients With Recurrent/Metastatic Head &amp; Neck Squamous Cell Carcinoma","recruitment_status":"Active, not recruiting","last_update_posted":"September 20, 2021"},"NCT03494322":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer (EACH)","recruitment_status":"Active, not recruiting","last_update_posted":"November 5, 2020"},"NCT03498378":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","recruitment_status":"Recruiting","last_update_posted":"October 19, 2020"},"NCT01860430":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"June 15, 2021"},"NCT02581137":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion","recruitment_status":"Active, not recruiting","last_update_posted":"September 16, 2021"},"NCT03074513":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors","recruitment_status":"Active, not recruiting","last_update_posted":"February 24, 2021"},"NCT01195922":{"publications":["30894372"],"projects":["1R33CA225291-01"],"title":"Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma","recruitment_status":"Completed","last_update_posted":"December 6, 2017"},"NCT01023386":{"publications":["30909651"],"projects":["1U54CA231652-01"],"title":"A Clinical Pharmacological Study of YM155 After Intravenous Infusion in Patients With Advanced Cancer","recruitment_status":"Completed","last_update_posted":"April 13, 2010"},"NCT00818480":{"publications":["30909651"],"projects":["1U54CA231652-01"],"title":"An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155","recruitment_status":"Completed","last_update_posted":"September 4, 2015"},"NCT01007292":{"publications":["30909651"],"projects":["1U54CA231652-01"],"title":"A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment","recruitment_status":"Completed","last_update_posted":"October 19, 2015"},"NCT01009775":{"publications":["30909651"],"projects":["1U54CA231652-01"],"title":"A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma","recruitment_status":"Completed","last_update_posted":"September 4, 2015"},"NCT01038804":{"publications":["30909651"],"projects":["1U54CA231652-01"],"title":"A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer","recruitment_status":"Completed","last_update_posted":"September 18, 2013"},"NCT00498914":{"publications":["30909651"],"projects":["1U54CA231652-01"],"title":"Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects","recruitment_status":"Terminated","last_update_posted":"September 4, 2015"},"NCT01100931":{"publications":["30909651"],"projects":["1U54CA231652-01"],"title":"A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)","recruitment_status":"Completed","last_update_posted":"October 19, 2015"},"NCT00514267":{"publications":["30909651"],"projects":["1U54CA231652-01"],"title":"An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors","recruitment_status":"Completed","last_update_posted":"August 13, 2015"},"NCT00281541":{"publications":["30909651"],"projects":["1U54CA231652-01"],"title":"A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma","recruitment_status":"Completed","last_update_posted":"June 7, 2012"},"NCT00328588":{"publications":["30909651"],"projects":["1U54CA231652-01"],"title":"LUCY: A Study for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in Patients Previously Treated With Chemotherapy","recruitment_status":"Completed","last_update_posted":"January 2, 2008"},"NCT00257478":{"publications":["30909651"],"projects":["1U54CA231652-01"],"title":"A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy","recruitment_status":"Completed","last_update_posted":"June 7, 2012"},"NCT02579226":{"publications":["30979745"],"projects":["3R01CA204915-02S1"],"title":"A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.","recruitment_status":"Completed","last_update_posted":"May 1, 2020"},"NCT01089101":{"publications":["31151904"],"projects":["2UM1CA081457-21"],"title":"Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma","recruitment_status":"Active, not recruiting","last_update_posted":"April 5, 2021"},"NCT02639546":{"publications":["31161239"],"projects":["1U2CCA233262-01"],"title":"Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi)","recruitment_status":"Active, not recruiting","last_update_posted":"July 2, 2021"},"NCT03095248":{"publications":["31161239"],"projects":["1U2CCA233262-01"],"title":"Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors (SEL-TH-1601)","recruitment_status":"Recruiting","last_update_posted":"July 23, 2021"},"NCT02523014":{"publications":["31161239"],"projects":["1U2CCA233262-01"],"title":"Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas","recruitment_status":"Recruiting","last_update_posted":"September 22, 2021"},"NCT02831257":{"publications":["31161239"],"projects":["1U2CCA233262-01"],"title":"AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas","recruitment_status":"Completed","last_update_posted":"December 22, 2020"},"NCT03071874":{"publications":["31161239"],"projects":["1U2CCA233262-01"],"title":"Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas","recruitment_status":"Active, not recruiting","last_update_posted":"January 20, 2021"},"NCT02060188":{"publications":["31383734"],"projects":["1U01CA233056-01"],"title":"An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread (CheckMate142)","recruitment_status":"Active, not recruiting","last_update_posted":"November 6, 2019"},"NCT02460198":{"publications":["31383734"],"projects":["1U01CA233056-01"],"title":"Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)","recruitment_status":"Completed","last_update_posted":"March 22, 2021"},"NCT03631641":{"publications":["31383734"],"projects":["1U01CA233056-01"],"title":"Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy","recruitment_status":"Active, not recruiting","last_update_posted":"May 15, 2020"},"NCT01461148":{"publications":["31383734","33842408"],"projects":["1U01CA233056-01","1U01CA233097-01"],"title":"Vaccination Against MSI Colorectal Cancer","recruitment_status":"Completed","last_update_posted":"June 23, 2015"},"NCT01885702":{"publications":["31383734"],"projects":["1U01CA233056-01"],"title":"Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI","recruitment_status":"Active, not recruiting","last_update_posted":"September 22, 2021"},"NCT02657005":{"publications":["31392992"],"projects":["3R01CA204915-02S1"],"title":"TK216 in Patients With Relapsed or Refractory Ewing Sarcoma","recruitment_status":"Recruiting","last_update_posted":"August 23, 2021"},"NCT00070109":{"publications":["31392992"],"projects":["3R01CA204915-02S1"],"title":"Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors","recruitment_status":"Completed","last_update_posted":"September 14, 2018"},"NCT03600649":{"publications":["31392992","32842875"],"projects":["3R01CA204915-02S1","1U54CA231641-01"],"title":"Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas","recruitment_status":"Recruiting","last_update_posted":"August 11, 2021"},"NCT01610570":{"publications":["31392992"],"projects":["3R01CA204915-02S1"],"title":"Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma","recruitment_status":"Terminated","last_update_posted":"March 2, 2018"},"NCT03637491":{"publications":["31409394"],"projects":["1U01DE028233-01"],"title":"A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors","recruitment_status":"Terminated","last_update_posted":"July 23, 2021"},"NCT03598270":{"publications":["31409394"],"projects":["1U01DE028233-01"],"title":"Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA)","recruitment_status":"Recruiting","last_update_posted":"August 13, 2021"},"NCT02243579":{"publications":["31532724"],"projects":["2UM1CA154967-07"],"title":"Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome","recruitment_status":"Completed","last_update_posted":"September 20, 2019"},"NCT01522443":{"publications":["31556911","33258687"],"projects":["1U01CA233046-01"],"title":"Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer (COMET-2)","recruitment_status":"Terminated","last_update_posted":"May 23, 2018"},"NCT01240538":{"publications":["31650024"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors","recruitment_status":"Completed","last_update_posted":"May 13, 2014"},"NCT01048892":{"publications":["31650024"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features","recruitment_status":"Completed","last_update_posted":"January 30, 2014"},"NCT02457845":{"publications":["31650024","31828566"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors","recruitment_status":"Active, not recruiting","last_update_posted":"July 8, 2021"},"NCT03043391":{"publications":["31650024","31828566"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children","recruitment_status":"Active, not recruiting","last_update_posted":"July 13, 2021"},"NCT02756845":{"publications":["31650024"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors","recruitment_status":"Recruiting","last_update_posted":"August 19, 2021"},"NCT00931931":{"publications":["31650024","31828566"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors","recruitment_status":"Completed","last_update_posted":"March 21, 2018"},"NCT01326104":{"publications":["31650024"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor (Re-MATCH)","recruitment_status":"Active, not recruiting","last_update_posted":"August 11, 2021"},"NCT02932956":{"publications":["31650024","31828566"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) (GAP)","recruitment_status":"Recruiting","last_update_posted":"January 8, 2021"},"NCT03500991":{"publications":["31650024","31828566"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors","recruitment_status":"Recruiting","last_update_posted":"March 15, 2021"},"NCT03638167":{"publications":["31650024","31828566"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors","recruitment_status":"Recruiting","last_update_posted":"March 15, 2021"},"NCT02315612":{"publications":["31650024","31828566"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies","recruitment_status":"Recruiting","last_update_posted":"September 5, 2021"},"NCT02772198":{"publications":["31650024"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies","recruitment_status":"Recruiting","last_update_posted":"November 3, 2020"},"NCT01555892":{"publications":["31650024"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE (GRALE)","recruitment_status":"Recruiting","last_update_posted":"December 23, 2020"},"NCT02892695":{"publications":["31650024","33007496"],"projects":["1U01CA232488-01","1U54CA232561-01A1","1U01CA239258-01"],"title":"PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma","recruitment_status":"Unknown","last_update_posted":"December 6, 2016"},"NCT02573896":{"publications":["31650024","32015013","33007496"],"projects":["1U01CA232488-01","1U54CA232561-01A1","1U01CA232491-01","1U01CA239258-01"],"title":"Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells","recruitment_status":"Recruiting","last_update_posted":"January 20, 2021"},"NCT02650648":{"publications":["31650024","32015013","33007496"],"projects":["1U01CA232488-01","1U54CA232561-01A1","1U01CA232491-01","1U01CA239258-01"],"title":"Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma","recruitment_status":"Active, not recruiting","last_update_posted":"October 5, 2020"},"NCT03209869":{"publications":["31650024"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2","recruitment_status":"Suspended\n                  \n      <!--","last_update_posted":"August 5, 2021"},"NCT03420963":{"publications":["31650024","32015013","33007496"],"projects":["1U01CA232488-01","1U54CA232561-01A1","1U01CA232491-01","1U01CA239258-01"],"title":"Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors","recruitment_status":"Recruiting","last_update_posted":"April 29, 2021"},"NCT02100891":{"publications":["31650024","33007496"],"projects":["1U01CA232488-01","1U54CA232561-01A1","1U01CA239258-01"],"title":"Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors (STIR)","recruitment_status":"Active, not recruiting","last_update_posted":"March 24, 2021"},"NCT01823198":{"publications":["31650024","33007496"],"projects":["1U01CA232488-01","1U54CA232561-01A1","1U01CA239258-01"],"title":"Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies","recruitment_status":"Active, not recruiting","last_update_posted":"December 4, 2020"},"NCT01904136":{"publications":["31650024"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia","recruitment_status":"Active, not recruiting","last_update_posted":"February 10, 2021"},"NCT02809092":{"publications":["31650024","33007496"],"projects":["1U01CA232488-01","1U54CA232561-01A1","1U01CA239258-01"],"title":"Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia","recruitment_status":"Unknown","last_update_posted":"October 15, 2019"},"NCT01898793":{"publications":["31650024"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)","recruitment_status":"Recruiting","last_update_posted":"May 21, 2021"},"NCT01619761":{"publications":["31650024"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"NK Cells in Cord Blood Transplantation","recruitment_status":"Active, not recruiting","last_update_posted":"February 11, 2020"},"NCT01714739":{"publications":["31704085"],"projects":["1U54CA232561-01A1"],"title":"A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors","recruitment_status":"Completed","last_update_posted":"December 14, 2020"},"NCT01750580":{"publications":["31704085"],"projects":["1U54CA232561-01A1"],"title":"Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor","recruitment_status":"Completed","last_update_posted":"July 22, 2015"},"NCT02331875":{"publications":["31704085"],"projects":["1U54CA232561-01A1"],"title":"Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity","recruitment_status":"Terminated","last_update_posted":"January 4, 2017"},"NCT02141451":{"publications":["31704085"],"projects":["1U54CA232561-01A1"],"title":"ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL","recruitment_status":"Completed","last_update_posted":"February 19, 2020"},"NCT02393859":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)","recruitment_status":"Active, not recruiting","last_update_posted":"December 8, 2020"},"NCT02435849":{"publications":["31828566","32001516"],"projects":["1U54CA232561-01A1","1R01CA226983-01"],"title":"Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL and High Risk B-cell ALL at First Relapse. Determine Feasibility and Safety of CTL019 Therapy in Pediatric Patients With High Risk B-cell ALL That Relapsed &lt; 6 Months Post All-HSCT. (ELIANA)","recruitment_status":"Active, not recruiting","last_update_posted":"June 30, 2021"},"NCT02559778":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PEDS-PLAN)","recruitment_status":"Recruiting","last_update_posted":"August 23, 2021"},"NCT03837899":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Durvalumab and Tremelimumab for Pediatric Malignancies","recruitment_status":"Recruiting","last_update_posted":"September 22, 2021"},"NCT04044378":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Famitinib Plus Camrelizumab &amp; Famitinib Alone &amp; Famitinib Plus Ifosfamide in Advanced Osteosarcoma","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"May 19, 2020"},"NCT02311621":{"publications":["31828566","32916097"],"projects":["1U54CA232561-01A1","1U54CA244438-01"],"title":"Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01","recruitment_status":"Recruiting","last_update_posted":"April 27, 2021"},"NCT03130959":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908)","recruitment_status":"Active, not recruiting","last_update_posted":"April 1, 2021"},"NCT03618381":{"publications":["31828566","32353955"],"projects":["1U54CA232561-01A1","1UG3CA244687-01"],"title":"EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults","recruitment_status":"Recruiting","last_update_posted":"April 19, 2021"},"NCT03334305":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas (ACTION)","recruitment_status":"Recruiting","last_update_posted":"August 12, 2021"},"NCT03448393":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies","recruitment_status":"Recruiting","last_update_posted":"September 5, 2021"},"NCT01192555":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma (ATOMIC)","recruitment_status":"Active, not recruiting","last_update_posted":"March 10, 2021"},"NCT02502708":{"publications":["31828566","33005623"],"projects":["1U54CA232561-01A1","1U01CA224151-01"],"title":"Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors","recruitment_status":"Completed","last_update_posted":"June 4, 2020"},"NCT03703050":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) (NIVO-ALCL)","recruitment_status":"Recruiting","last_update_posted":"July 7, 2021"},"NCT03907488":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma","recruitment_status":"Recruiting","last_update_posted":"September 21, 2021"},"NCT02789228":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors (REST)","recruitment_status":"Recruiting","last_update_posted":"February 25, 2021"},"NCT03396575":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I) (BRAVO)","recruitment_status":"Recruiting","last_update_posted":"July 13, 2021"},"NCT03911388":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors","recruitment_status":"Recruiting","last_update_posted":"July 8, 2021"},"NCT03178032":{"publications":["31828566","32332014"],"projects":["1U54CA232561-01A1","1U01CA224160-01"],"title":"Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas","recruitment_status":"Active, not recruiting","last_update_posted":"July 16, 2020"},"NCT02962167":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT","recruitment_status":"Recruiting","last_update_posted":"June 30, 2021"},"NCT02444546":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors","recruitment_status":"Active, not recruiting","last_update_posted":"August 18, 2021"},"NCT03495921":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma (VITA)","recruitment_status":"Active, not recruiting","last_update_posted":"August 18, 2021"},"NCT00790413":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Haploidentical Stem Cell Transplantation in Neuroblastoma","recruitment_status":"Active, not recruiting","last_update_posted":"February 21, 2021"},"NCT02793466":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Durvalumab in Pediatric and Adolescent Patients","recruitment_status":"Unknown","last_update_posted":"January 30, 2019"},"NCT01860937":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia","recruitment_status":"Active, not recruiting","last_update_posted":"July 6, 2021"},"NCT03006848":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma","recruitment_status":"Active, not recruiting","last_update_posted":"September 16, 2021"},"NCT00634231":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors","recruitment_status":"Active, not recruiting","last_update_posted":"January 27, 2021"},"NCT02511132":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"A Two-part Phase IIb Trial of Vigil in Ewing's Sarcoma","recruitment_status":"Completed","last_update_posted":"February 4, 2021"},"NCT03299309":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma (PRiME)","recruitment_status":"Suspended\n                  \n      <!--","last_update_posted":"May 25, 2021"},"NCT02028455":{"publications":["31828566","33914708"],"projects":["1U54CA232561-01A1","1U01CA247548-01"],"title":"A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia","recruitment_status":"Active, not recruiting","last_update_posted":"January 29, 2021"},"NCT03643276":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017","recruitment_status":"Recruiting","last_update_posted":"July 7, 2021"},"NCT03244306":{"publications":["31828566","33914708"],"projects":["1U54CA232561-01A1","1U01CA247548-01"],"title":"A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma (PLAT-04)","recruitment_status":"Active, not recruiting","last_update_posted":"January 19, 2021"},"NCT03186118":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia","recruitment_status":"Recruiting","last_update_posted":"March 25, 2021"},"NCT03605589":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"April 1, 2021"},"NCT03330691":{"publications":["31828566","33914708"],"projects":["1U54CA232561-01A1","1U01CA247548-01"],"title":"A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia","recruitment_status":"Recruiting","last_update_posted":"May 24, 2021"},"NCT00902044":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma","recruitment_status":"Active, not recruiting","last_update_posted":"August 24, 2021"},"NCT03769467":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)","recruitment_status":"Active, not recruiting","last_update_posted":"February 3, 2021"},"NCT02960230":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas","recruitment_status":"Recruiting","last_update_posted":"August 25, 2021"},"NCT01700946":{"publications":["31828566","33007496"],"projects":["1U54CA232561-01A1","1U01CA239258-01"],"title":"Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma","recruitment_status":"Completed","last_update_posted":"August 24, 2021"},"NCT01169584":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients","recruitment_status":"Completed","last_update_posted":"January 21, 2016"},"NCT03359018":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma (APFAO)","recruitment_status":"Completed","last_update_posted":"May 19, 2020"},"NCT02403778":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma","recruitment_status":"Active, not recruiting","last_update_posted":"September 23, 2020"},"NCT03089203":{"publications":["31845905","32015021","33820953"],"projects":["1R01CA226983-01","1U54CA244711-01","1U01CA239258-01","1U01CA233100-01","1U01CA244452-01"],"title":"CART-PSMA-TGF&#946;RDN Cells for Castrate-Resistant Prostate Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"January 14, 2021"},"NCT01747486":{"publications":["31845905"],"projects":["1R01CA226983-01","1U54CA244711-01"],"title":"Dose Optimization Trial of CD19 Redirected Autologous T Cells","recruitment_status":"Completed","last_update_posted":"August 30, 2019"},"NCT01626495":{"publications":["31845905","32001516","34006631"],"projects":["1R01CA226983-01","1U54CA244711-01","1U01CA232361-01A1"],"title":"Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma (Pedi CART19)","recruitment_status":"Completed","last_update_posted":"March 23, 2020"},"NCT01029366":{"publications":["31845905"],"projects":["1R01CA226983-01","1U54CA244711-01"],"title":"CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy","recruitment_status":"Completed","last_update_posted":"June 26, 2019"},"NCT02640209":{"publications":["31845905"],"projects":["1R01CA226983-01","1U54CA244711-01"],"title":"Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)","recruitment_status":"Terminated","last_update_posted":"May 7, 2020"},"NCT01811992":{"publications":["31959027","32332014"],"projects":["1U01CA224160-01"],"title":"Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma","recruitment_status":"Completed","last_update_posted":"August 31, 2021"},"NCT00002824":{"publications":["31959027"],"projects":["1U01CA224160-01"],"title":"Gene Therapy in Treating Patients With Primary Brain Tumors","recruitment_status":"Completed","last_update_posted":"March 13, 2019"},"NCT02017717":{"publications":["31959027"],"projects":["1U01CA224160-01"],"title":"A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients (CheckMate 143)","recruitment_status":"Active, not recruiting","last_update_posted":"April 19, 2021"},"NCT02311920":{"publications":["31959027"],"projects":["1U01CA224160-01"],"title":"Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma","recruitment_status":"Active, not recruiting","last_update_posted":"July 6, 2021"},"NCT02414165":{"publications":["31959027"],"projects":["1U01CA224160-01"],"title":"The Toca 5 Trial: Toca 511 &amp; Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma (Toca5)","recruitment_status":"Terminated","last_update_posted":"February 7, 2020"},"NCT00805376":{"publications":["31959027"],"projects":["1U01CA224160-01"],"title":"DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas","recruitment_status":"Completed","last_update_posted":"July 16, 2018"},"NCT01472003":{"publications":["31959027"],"projects":["1U01CA224160-01"],"title":"An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types","recruitment_status":"Completed","last_update_posted":"January 14, 2013"},"NCT01255657":{"publications":["31959027"],"projects":["1U01CA224160-01"],"title":"A Study of ABT-806 in Subjects With Advanced Solid Tumor Types","recruitment_status":"Completed","last_update_posted":"November 21, 2017"},"NCT01406119":{"publications":["31959027"],"projects":["1U01CA224160-01"],"title":"An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors","recruitment_status":"Completed","last_update_posted":"January 27, 2017"},"NCT02381886":{"publications":["31959027"],"projects":["1U01CA224160-01"],"title":"A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations","recruitment_status":"Active, not recruiting","last_update_posted":"July 26, 2021"},"NCT02977689":{"publications":["31959027"],"projects":["1U01CA224160-01"],"title":"Trial of IDH305 in IDH1 Mutant Grade II or III Glioma","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"December 20, 2017"},"NCT02253212":{"publications":["31959027"],"projects":["1U01CA224160-01"],"title":"Safety of BBB Opening With the SonoCloud (SONOCLOUD)","recruitment_status":"Completed","last_update_posted":"October 12, 2018"},"NCT02573324":{"publications":["31959027"],"projects":["1U01CA224160-01"],"title":"A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)","recruitment_status":"Active, not recruiting","last_update_posted":"May 24, 2021"},"NCT02343406":{"publications":["31959027"],"projects":["1U01CA224160-01"],"title":"Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas (INTELLANCE-2)","recruitment_status":"Completed","last_update_posted":"May 22, 2020"},"NCT00458601":{"publications":["31959027"],"projects":["1U01CA224160-01"],"title":"Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme (ACT III)","recruitment_status":"Completed","last_update_posted":"January 16, 2018"},"NCT03899857":{"publications":["31959027"],"projects":["1U01CA224160-01"],"title":"Pembrolizumab for Newly Diagnosed Glioblastoma (PERGOLA)","recruitment_status":"Recruiting","last_update_posted":"December 16, 2020"},"NCT03726515":{"publications":["31959027","32015021"],"projects":["1U01CA224160-01","1U01CA239258-01"],"title":"CART-EGFRvIII + Pembrolizumab in GBM","recruitment_status":"Completed","last_update_posted":"March 3, 2021"},"NCT02661282":{"publications":["31959027"],"projects":["1U01CA224160-01"],"title":"Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma","recruitment_status":"Active, not recruiting","last_update_posted":"July 22, 2020"},"NCT01491893":{"publications":["31959027"],"projects":["1U01CA224160-01"],"title":"PVSRIPO for Recurrent Glioblastoma (GBM) (PVSRIPO)","recruitment_status":"Active, not recruiting","last_update_posted":"January 12, 2021"},"NCT01130142":{"publications":["31980749","34025067"],"projects":["1U01CA224193-01","1U01CA224348-01","1U54CA224083-01"],"title":"A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer","recruitment_status":"Completed","last_update_posted":"March 6, 2017"},"NCT01850628":{"publications":["31988290"],"projects":["1U54CA233223-01"],"title":"NSABP Biospecimen Discovery Project","recruitment_status":"Active, not recruiting","last_update_posted":"September 10, 2020"},"NCT02228096":{"publications":["32001516"],"projects":["1R01CA226983-01"],"title":"Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients (ENSIGN)","recruitment_status":"Completed","last_update_posted":"November 23, 2020"},"NCT02030847":{"publications":["32001516"],"projects":["1R01CA226983-01"],"title":"Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia","recruitment_status":"Completed","last_update_posted":"August 30, 2019"},"NCT01514201":{"publications":["32009149","32241771"],"projects":["2UM1CA081457-21"],"title":"Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas","recruitment_status":"Completed","last_update_posted":"August 13, 2019"},"NCT00770471":{"publications":["32009149"],"projects":["2UM1CA081457-21"],"title":"ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","recruitment_status":"Completed","last_update_posted":"June 27, 2018"},"NCT02484443":{"publications":["32015013","34244307"],"projects":["1U01CA232491-01","1U54CA232561-01A1"],"title":"Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma","recruitment_status":"Active, not recruiting","last_update_posted":"August 5, 2021"},"NCT01419834":{"publications":["32015013"],"projects":["1U01CA232491-01"],"title":"Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors","recruitment_status":"Active, not recruiting","last_update_posted":"August 25, 2021"},"NCT01662804":{"publications":["32015013"],"projects":["1U01CA232491-01"],"title":"Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors","recruitment_status":"Completed","last_update_posted":"May 27, 2021"},"NCT02159443":{"publications":["32015013"],"projects":["1U01CA232491-01"],"title":"Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody","recruitment_status":"Completed","last_update_posted":"November 5, 2020"},"NCT00743496":{"publications":["32015013"],"projects":["1U01CA232491-01"],"title":"A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma","recruitment_status":"Completed","last_update_posted":"August 17, 2017"},"NCT02982941":{"publications":["32015013"],"projects":["1U01CA232491-01"],"title":"Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors","recruitment_status":"Completed","last_update_posted":"January 30, 2020"},"NCT00582608":{"publications":["32015013"],"projects":["1U01CA232491-01"],"title":"Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9","recruitment_status":"Terminated","last_update_posted":"March 1, 2017"},"NCT02173093":{"publications":["32015013"],"projects":["1U01CA232491-01"],"title":"Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma","recruitment_status":"Unknown","last_update_posted":"January 29, 2019"},"NCT03860207":{"publications":["32015013"],"projects":["1U01CA232491-01"],"title":"Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers","recruitment_status":"Recruiting","last_update_posted":"May 25, 2021"},"NCT01218867":{"publications":["32015021","32916097"],"projects":["1U01CA239258-01","1U54CA244438-01"],"title":"CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer","recruitment_status":"Terminated","last_update_posted":"December 10, 2019"},"NCT03294954":{"publications":["32015021"],"projects":["1U01CA239258-01"],"title":"GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma (GINAKIT2)","recruitment_status":"Recruiting","last_update_posted":"January 15, 2021"},"NCT03579927":{"publications":["32015021"],"projects":["1U01CA239258-01"],"title":"CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"January 29, 2020"},"NCT03056339":{"publications":["32015021","33007496"],"projects":["1U01CA239258-01"],"title":"Umbilical &amp; Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies","recruitment_status":"Recruiting","last_update_posted":"July 19, 2021"},"NCT03545815":{"publications":["32015021"],"projects":["1U01CA239258-01"],"title":"Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.","recruitment_status":"Recruiting","last_update_posted":"August 10, 2020"},"NCT02414269":{"publications":["32015021"],"projects":["1U01CA239258-01"],"title":"Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin","recruitment_status":"Recruiting","last_update_posted":"April 1, 2021"},"NCT04003649":{"publications":["32015021"],"projects":["1U01CA239258-01"],"title":"IL13Ralpha2-Targeted Chimeric Antigen Receptor (CAR) T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With Recurrent or Refractory Glioblastoma","recruitment_status":"Recruiting","last_update_posted":"December 9, 2020"},"NCT02498912":{"publications":["32015021","32916097"],"projects":["1U01CA239258-01","1U54CA244438-01"],"title":"Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors","recruitment_status":"Active, not recruiting","last_update_posted":"February 8, 2021"},"NCT04093648":{"publications":["32015021"],"projects":["1U01CA239258-01"],"title":"T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"May 20, 2020"},"NCT03721068":{"publications":["32015021"],"projects":["1U01CA239258-01"],"title":"Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma","recruitment_status":"Recruiting","last_update_posted":"July 7, 2021"},"NCT02569723":{"publications":["32029633"],"projects":["1U54CA233306-01"],"title":"Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy","recruitment_status":"Completed","last_update_posted":"March 30, 2021"},"NCT02255461":{"publications":["32078691"],"projects":["2UM1CA081457-21","1U01CA224160-01"],"title":"Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors","recruitment_status":"Terminated","last_update_posted":"March 2, 2021"},"NCT03387020":{"publications":["32078691"],"projects":["1U01CA224160-01"],"title":"Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors","recruitment_status":"Completed","last_update_posted":"August 27, 2021"},"NCT03355794":{"publications":["32078691"],"projects":["1U01CA224160-01"],"title":"A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)","recruitment_status":"Active, not recruiting","last_update_posted":"August 27, 2021"},"NCT02644460":{"publications":["32078691"],"projects":["1U01CA224160-01"],"title":"Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors (AflacST1501)","recruitment_status":"Recruiting","last_update_posted":"March 4, 2021"},"NCT02717455":{"publications":["32078691"],"projects":["1U01CA224160-01"],"title":"Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma (PBTC-047)","recruitment_status":"Recruiting","last_update_posted":"September 22, 2021"},"NCT03632317":{"publications":["32078691"],"projects":["1U01CA224160-01"],"title":"A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"August 19, 2019"},"NCT03566199":{"publications":["32078691"],"projects":["1U01CA224160-01"],"title":"MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma (PNOC015)","recruitment_status":"Completed","last_update_posted":"April 13, 2021"},"NCT00058474":{"publications":["32091598","33345351"],"projects":["1U01CA232859-01"],"title":"Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer","recruitment_status":"Unknown","last_update_posted":"March 23, 2016"},"NCT03184571":{"publications":["32102694"],"projects":["1U24CA224316-01"],"title":"Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC","recruitment_status":"Recruiting","last_update_posted":"May 29, 2020"},"NCT00480363":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression (QUIREDEX)","recruitment_status":"Completed","last_update_posted":"July 31, 2013"},"NCT01169337":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma","recruitment_status":"Active, not recruiting","last_update_posted":"May 18, 2021"},"NCT02681302":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence (CPIT001)","recruitment_status":"Active, not recruiting","last_update_posted":"May 4, 2021"},"NCT02252263":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma","recruitment_status":"Completed","last_update_posted":"November 1, 2017"},"NCT02654132":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)","recruitment_status":"Active, not recruiting","last_update_posted":"July 14, 2020"},"NCT02289222":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma","recruitment_status":"Terminated","last_update_posted":"November 5, 2019"},"NCT02036502":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)","recruitment_status":"Terminated","last_update_posted":"April 8, 2021"},"NCT02726581":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma (CheckMate 602)","recruitment_status":"Active, not recruiting","last_update_posted":"August 6, 2021"},"NCT02076009":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma","recruitment_status":"Active, not recruiting","last_update_posted":"August 9, 2021"},"NCT02136134":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma","recruitment_status":"Active, not recruiting","last_update_posted":"September 20, 2021"},"NCT02431208":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)","recruitment_status":"Completed","last_update_posted":"April 2, 2021"},"NCT01592370":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma","recruitment_status":"Active, not recruiting","last_update_posted":"June 18, 2021"},"NCT03357952":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma","recruitment_status":"Active, not recruiting","last_update_posted":"September 20, 2021"},"NCT03111992":{"publications":["32149732","33777050"],"projects":["1U01CA244291-01"],"title":"Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma","recruitment_status":"Completed","last_update_posted":"September 9, 2020"},"NCT03015922":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma (MUKeleven)","recruitment_status":"Active, not recruiting","last_update_posted":"January 22, 2020"},"NCT02514382":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma","recruitment_status":"Unknown","last_update_posted":"May 3, 2019"},"NCT02101944":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma","recruitment_status":"Recruiting","last_update_posted":"August 13, 2021"},"NCT00450814":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma","recruitment_status":"Completed","last_update_posted":"December 16, 2019"},"NCT02192775":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus","recruitment_status":"Completed","last_update_posted":"October 19, 2020"},"NCT03017820":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma","recruitment_status":"Recruiting","last_update_posted":"August 27, 2021"},"NCT01858558":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma","recruitment_status":"Completed","last_update_posted":"June 29, 2020"},"NCT02728102":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)","recruitment_status":"Active, not recruiting","last_update_posted":"September 9, 2021"},"NCT03090659":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma (LEGEND-2)","recruitment_status":"Active, not recruiting","last_update_posted":"September 2, 2021"},"NCT03093168":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma","recruitment_status":"Unknown","last_update_posted":"February 27, 2019"},"NCT03288493":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)","recruitment_status":"Recruiting","last_update_posted":"September 14, 2021"},"NCT03318861":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma","recruitment_status":"Active, not recruiting","last_update_posted":"June 28, 2021"},"NCT02658929":{"publications":["32149732","33558511"],"projects":["1U01CA244291-01","2P01CA155258-06"],"title":"Study of bb2121 in Multiple Myeloma","recruitment_status":"Active, not recruiting","last_update_posted":"December 4, 2020"},"NCT02215967":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma","recruitment_status":"Completed","last_update_posted":"October 8, 2019"},"NCT03672318":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma","recruitment_status":"Recruiting","last_update_posted":"June 30, 2021"},"NCT03958656":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma","recruitment_status":"Completed","last_update_posted":"September 9, 2021"},"NCT03455972":{"publications":["32149732"],"projects":["1U01CA244291-01"],"title":"Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT","recruitment_status":"Recruiting","last_update_posted":"May 19, 2021"},"NCT03502577":{"publications":["32149732","33914708"],"projects":["1U01CA244291-01","1U01CA247548-01"],"title":"BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma","recruitment_status":"Suspended\n                  \n      <!--","last_update_posted":"August 2, 2021"},"NCT02304458":{"publications":["32192573"],"projects":["5UM1CA228823-03"],"title":"Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas","recruitment_status":"Active, not recruiting","last_update_posted":"September 17, 2021"},"NCT02927769":{"publications":["32192573"],"projects":["5UM1CA228823-03"],"title":"A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment (CheckMate 744)","recruitment_status":"Recruiting","last_update_posted":"June 11, 2020"},"NCT02843165":{"publications":["32193227"],"projects":["1U01DE028227-01"],"title":"Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease","recruitment_status":"Recruiting","last_update_posted":"January 25, 2021"},"NCT00648648":{"publications":["32209571"],"projects":["1U01CA233084-01"],"title":"A Dose Escalation Study of MK-1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)","recruitment_status":"Completed","last_update_posted":"April 5, 2019"},"NCT02936609":{"publications":["32294251"],"projects":["1P50CA244289-01"],"title":"Assessing Community Cancer Care After Insurance ExpanSionS (ACCESS)","recruitment_status":"Completed","last_update_posted":"August 30, 2021"},"NCT03545763":{"publications":["32294251"],"projects":["1P50CA244289-01"],"title":"Evaluating Control of Hypertension - Effect of Social Determinants (ECHOES)","recruitment_status":"Active, not recruiting","last_update_posted":"March 23, 2021"},"NCT03433183":{"publications":["32353955"],"projects":["1UG3CA244687-01"],"title":"SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors","recruitment_status":"Recruiting","last_update_posted":"September 18, 2020"},"NCT02008877":{"publications":["32353955"],"projects":["1UG3CA244687-01"],"title":"SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)","recruitment_status":"Completed","last_update_posted":"May 15, 2019"},"NCT02584647":{"publications":["32353955"],"projects":["1UG3CA244687-01"],"title":"PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors (PLX3397)","recruitment_status":"Recruiting","last_update_posted":"August 31, 2021"},"NCT03009201":{"publications":["32353955"],"projects":["1UG3CA244687-01"],"title":"Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery","recruitment_status":"Active, not recruiting","last_update_posted":"June 15, 2021"},"NCT02691026":{"publications":["32353955"],"projects":["1UG3CA244687-01"],"title":"A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery","recruitment_status":"Terminated","last_update_posted":"June 23, 2021"},"NCT02834013":{"publications":["32353955"],"projects":["1UG3CA244687-01"],"title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","recruitment_status":"Recruiting","last_update_posted":"September 22, 2021"},"NCT04222413":{"publications":["32353955"],"projects":["1UG3CA244687-01"],"title":"Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors","recruitment_status":"Recruiting","last_update_posted":"September 5, 2021"},"NCT03880123":{"publications":["32353955"],"projects":["1UG3CA244687-01"],"title":"Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"November 27, 2020"},"NCT03665285":{"publications":["32376804"],"projects":["1U01CA232491-01"],"title":"A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors","recruitment_status":"Recruiting","last_update_posted":"August 18, 2021"},"NCT03615040":{"publications":["32376804"],"projects":["1U01CA232491-01"],"title":"Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP) (COPD-ST2OP)","recruitment_status":"Completed","last_update_posted":"February 25, 2021"},"NCT01964300":{"publications":["32393959"],"projects":["2UM1CA081457-21"],"title":"Peginterferon Alfa-2b in Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery","recruitment_status":"Terminated","last_update_posted":"February 24, 2020"},"NCT03212274":{"publications":["32459988"],"projects":["1U01CA224146-01"],"title":"Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations","recruitment_status":"Recruiting","last_update_posted":"September 9, 2021"},"NCT02588105":{"publications":["32459988","32541866"],"projects":["1U01CA224146-01","1U54CA244719-01"],"title":"Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer (AToM)","recruitment_status":"Active, not recruiting","last_update_posted":"August 18, 2021"},"NCT03462342":{"publications":["32459988"],"projects":["1U01CA224146-01"],"title":"Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer (CAPRI)","recruitment_status":"Recruiting","last_update_posted":"January 27, 2021"},"NCT04149145":{"publications":["32459988"],"projects":["1U01CA224146-01"],"title":"Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer (PARP)","recruitment_status":"Not yet recruiting","last_update_posted":"July 6, 2021"},"NCT03669601":{"publications":["32459988"],"projects":["1U01CA224146-01"],"title":"AZD6738 &amp; Gemcitabine as Combination Therapy (ATRiUM)","recruitment_status":"Recruiting","last_update_posted":"June 4, 2021"},"NCT04095273":{"publications":["32459988"],"projects":["1U01CA224146-01"],"title":"Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug","recruitment_status":"Recruiting","last_update_posted":"September 5, 2021"},"NCT03057145":{"publications":["32459988"],"projects":["1U01CA224146-01"],"title":"Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors","recruitment_status":"Completed","last_update_posted":"September 2, 2021"},"NCT02632448":{"publications":["32459988"],"projects":["1U01CA224146-01"],"title":"A Study of LY2880070 in Participants With Advanced or Metastatic Cancer","recruitment_status":"Recruiting","last_update_posted":"September 16, 2020"},"NCT03495323":{"publications":["32459988"],"projects":["1U01CA224146-01"],"title":"A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors","recruitment_status":"Completed","last_update_posted":"April 15, 2021"},"NCT03724890":{"publications":["32459988"],"projects":["1U01CA224146-01"],"title":"Study of Avelumab-M3814 Combinations","recruitment_status":"Recruiting","last_update_posted":"August 17, 2021"},"NCT03770689":{"publications":["32459988"],"projects":["1U01CA224146-01"],"title":"Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"August 31, 2021"},"NCT04197713":{"publications":["32459988"],"projects":["1U01CA224146-01"],"title":"Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study","recruitment_status":"Recruiting","last_update_posted":"June 18, 2021"},"NCT03012477":{"publications":["32459988"],"projects":["1U01CA224146-01"],"title":"CISPLATIN + AZD-1775 In Breast Cancer","recruitment_status":"Completed","last_update_posted":"June 28, 2021"},"NCT02617277":{"publications":["32459988"],"projects":["1U01CA224146-01"],"title":"Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours","recruitment_status":"Active, not recruiting","last_update_posted":"September 5, 2021"},"NCT00238238":{"publications":["32470440"],"projects":["1U01CA233046-01"],"title":"Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab","recruitment_status":"Completed","last_update_posted":"March 15, 2017"},"NCT01454297":{"publications":["32471990","33963182"],"projects":["1U2CCA233303-01"],"title":"Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass)","recruitment_status":"Active, not recruiting","last_update_posted":"August 16, 2018"},"NCT02451423":{"publications":["32497499"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Neoadjuvant Atezolizumab in Localized Bladder Cancer","recruitment_status":"Recruiting","last_update_posted":"March 30, 2020"},"NCT03010176":{"publications":["32541866"],"projects":["1U54CA244719-01"],"title":"Study of MK-1454 Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)","recruitment_status":"Active, not recruiting","last_update_posted":"April 21, 2021"},"NCT03172936":{"publications":["32541866"],"projects":["1U54CA244719-01"],"title":"Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas","recruitment_status":"Completed","last_update_posted":"February 24, 2021"},"NCT03225105":{"publications":["32541866"],"projects":["1U54CA244719-01"],"title":"M3541 in Combination With Radiotherapy in Subjects With Solid Tumors","recruitment_status":"Completed","last_update_posted":"September 14, 2020"},"NCT02494583":{"publications":["32541866"],"projects":["1U54CA244719-01"],"title":"Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)","recruitment_status":"Active, not recruiting","last_update_posted":"March 10, 2021"},"NCT03189719":{"publications":["32541866"],"projects":["1U54CA244719-01"],"title":"First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)","recruitment_status":"Active, not recruiting","last_update_posted":"September 20, 2021"},"NCT01120288":{"publications":["32550915"],"projects":["1U01DE029255-01"],"title":"A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases","recruitment_status":"Completed","last_update_posted":"July 5, 2018"},"NCT00466583":{"publications":["32550915"],"projects":["1U01DE029255-01"],"title":"Phase 1 Study of EZN-2968 Weekly in Adult Patients With Advanced Solid Tumors or Lymphoma","recruitment_status":"Completed","last_update_posted":"July 7, 2011"},"NCT00400946":{"publications":["32606318"],"projects":["3R00CA181500-04S1"],"title":"Treatment of Acute Lymphoblastic Leukemia in Children","recruitment_status":"Completed","last_update_posted":"November 20, 2019"},"NCT00408005":{"publications":["32606318"],"projects":["3R00CA181500-04S1"],"title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","recruitment_status":"Active, not recruiting","last_update_posted":"May 25, 2021"},"NCT03904862":{"publications":["32615532"],"projects":["2UM1CA081457-21"],"title":"Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery","recruitment_status":"Recruiting","last_update_posted":"September 22, 2021"},"NCT03765918":{"publications":["32665297"],"projects":["3U24CA237719-02S1"],"title":"Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)","recruitment_status":"Recruiting","last_update_posted":"September 16, 2021"},"NCT03153462":{"publications":["32669372"],"projects":["1U01CA247576-01"],"title":"Axicabtagene Ciloleucel Expanded Access Study (ZUMA-9)","recruitment_status":"Approved for marketing","last_update_posted":"May 17, 2021"},"NCT03958383":{"publications":["32690669","32849544","33826741"],"projects":["1U01CA233102-01","1U54CA232568-01"],"title":"IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma","recruitment_status":"Recruiting","last_update_posted":"November 27, 2020"},"NCT03059485":{"publications":["32710608"],"projects":["1U01CA233084-01"],"title":"DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission","recruitment_status":"Recruiting","last_update_posted":"October 22, 2020"},"NCT04025216":{"publications":["32710608"],"projects":["1U01CA233084-01"],"title":"A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers","recruitment_status":"Recruiting","last_update_posted":"April 29, 2021"},"NCT01415882":{"publications":["32724061"],"projects":["1U54CA224018-01"],"title":"Ixazomib in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib","recruitment_status":"Recruiting","last_update_posted":"April 8, 2021"},"NCT04358276":{"publications":["32746799"],"projects":["1R01CA249460-01"],"title":"Technology-Enabled Activation of Skin Cancer Screening for Stem Cell Transplant Survivors and Their Primary Care Providers, TEACH Study","recruitment_status":"Recruiting","last_update_posted":"February 16, 2021"},"NCT02215850":{"publications":["32822815"],"projects":["1U2CCA233280-01"],"title":"Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours","recruitment_status":"Completed","last_update_posted":"May 17, 2016"},"NCT03450018":{"publications":["32822815"],"projects":["1U2CCA233280-01"],"title":"A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX (SLC-0111-17-01)","recruitment_status":"Recruiting","last_update_posted":"March 15, 2021"},"NCT03375086":{"publications":["32822815"],"projects":["1U2CCA233280-01"],"title":"A Study of APX3330 in Patients With Advanced Solid Tumors (APX3330)","recruitment_status":"Completed","last_update_posted":"September 7, 2020"},"NCT03447769":{"publications":["32856614"],"projects":["1U2CCA233238-01"],"title":"Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T&gt;5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A (Canopy-A)","recruitment_status":"Recruiting","last_update_posted":"September 13, 2021"},"NCT03631199":{"publications":["32856614"],"projects":["1U2CCA233238-01"],"title":"Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1)","recruitment_status":"Active, not recruiting","last_update_posted":"September 13, 2021"},"NCT03300817":{"publications":["32856614"],"projects":["1U2CCA233238-01"],"title":"MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer","recruitment_status":"Recruiting","last_update_posted":"September 8, 2021"},"NCT03634241":{"publications":["32856614"],"projects":["1U2CCA233238-01"],"title":"Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study","recruitment_status":"Recruiting","last_update_posted":"June 1, 2021"},"NCT02927301":{"publications":["32856614"],"projects":["1U2CCA233238-01"],"title":"A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)","recruitment_status":"Active, not recruiting","last_update_posted":"May 17, 2021"},"NCT02716038":{"publications":["32856614"],"projects":["1U2CCA233238-01"],"title":"Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC","recruitment_status":"Active, not recruiting","last_update_posted":"April 15, 2021"},"NCT03393936":{"publications":["32916097"],"projects":["1U54CA244438-01"],"title":"Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma","recruitment_status":"Active, not recruiting","last_update_posted":"April 7, 2020"},"NCT02541370":{"publications":["32916097"],"projects":["1U54CA244438-01"],"title":"Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133","recruitment_status":"Completed","last_update_posted":"December 17, 2019"},"NCT02862704":{"publications":["32916097"],"projects":["1U54CA244438-01"],"title":"A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART)","recruitment_status":"Unknown","last_update_posted":"August 11, 2016"},"NCT04045847":{"publications":["32916097"],"projects":["1U54CA244438-01"],"title":"CD147-CART Cells in Patients With Recurrent Malignant Glioma.","recruitment_status":"Recruiting","last_update_posted":"May 7, 2020"},"NCT02830724":{"publications":["32916097"],"projects":["1U54CA244438-01"],"title":"Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers","recruitment_status":"Suspended\n                  \n      <!--","last_update_posted":"January 29, 2021"},"NCT03198052":{"publications":["32916097"],"projects":["1U54CA244438-01"],"title":"HER2/Mesothelin/Lewis-Y/PSCA/MUC1/GPC3/AXL/EGFR/B7-H3/Claudin18.2-CAR-T Cells Immunotherapy Against Cancers","recruitment_status":"Recruiting","last_update_posted":"December 1, 2020"},"NCT01373047":{"publications":["32916097"],"projects":["1U54CA244438-01"],"title":"CEA-Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti-CEA Designer T Cells (HITM)","recruitment_status":"Completed","last_update_posted":"July 30, 2013"},"NCT03159819":{"publications":["32916097"],"projects":["1U54CA244438-01"],"title":"Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma","recruitment_status":"Recruiting","last_update_posted":"March 12, 2018"},"NCT02331693":{"publications":["32916097"],"projects":["1U54CA244438-01"],"title":"CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR","recruitment_status":"Unknown","last_update_posted":"January 6, 2015"},"NCT02915445":{"publications":["32916097"],"projects":["1U54CA244438-01"],"title":"EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast Cancer","recruitment_status":"Recruiting","last_update_posted":"April 8, 2019"},"NCT03423992":{"publications":["32916097"],"projects":["1U54CA244438-01"],"title":"Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas","recruitment_status":"Recruiting","last_update_posted":"June 15, 2021"},"NCT01722149":{"publications":["32916097"],"projects":["1U54CA244438-01"],"title":"Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma","recruitment_status":"Completed","last_update_posted":"August 7, 2019"},"NCT00019136":{"publications":["32916097"],"projects":["1U54CA244438-01"],"title":"Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer","recruitment_status":"Completed","last_update_posted":"April 29, 2015"},"NCT00085930":{"publications":["32916097"],"projects":["1U54CA244438-01"],"title":"Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients (NESTLES)","recruitment_status":"Active, not recruiting","last_update_posted":"January 8, 2021"},"NCT02959151":{"publications":["32916097"],"projects":["1U54CA244438-01"],"title":"A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy","recruitment_status":"Unknown","last_update_posted":"November 8, 2016"},"NCT00730613":{"publications":["32916097"],"projects":["1U54CA244438-01"],"title":"Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma","recruitment_status":"Completed","last_update_posted":"October 9, 2017"},"NCT02442297":{"publications":["32916097"],"projects":["1U54CA244438-01"],"title":"T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors (iCAR)","recruitment_status":"Recruiting","last_update_posted":"September 10, 2021"},"NCT02930993":{"publications":["32916097"],"projects":["1U54CA244438-01"],"title":"Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors","recruitment_status":"Unknown","last_update_posted":"October 12, 2016"},"NCT01837602":{"publications":["32916097"],"projects":["1U54CA244438-01"],"title":"cMet CAR RNA T Cells Targeting Breast Cancer","recruitment_status":"Completed","last_update_posted":"October 19, 2018"},"NCT02617134":{"publications":["32916097"],"projects":["1U54CA244438-01"],"title":"CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor","recruitment_status":"Unknown","last_update_posted":"December 6, 2016"},"NCT01929239":{"publications":["32916097"],"projects":["1U54CA244438-01"],"title":"Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning","recruitment_status":"Suspended\n                  \n      <!--","last_update_posted":"June 17, 2016"},"NCT02706392":{"publications":["32916097","33914708"],"projects":["1U54CA244438-01","1U01CA247548-01"],"title":"Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies","recruitment_status":"Recruiting","last_update_posted":"July 8, 2021"},"NCT03278340":{"publications":["32942054"],"projects":["1R01CA210259-01A1"],"title":"Using Technology to Scale-Up an Occupational Sun Protection Policy Program (SSW-T)","recruitment_status":"Enrolling by invitation","last_update_posted":"July 9, 2021"},"NCT02181413":{"publications":["32945549"],"projects":["1U01CA244291-01"],"title":"A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant","recruitment_status":"Active, not recruiting","last_update_posted":"March 9, 2021"},"NCT00114101":{"publications":["32945549"],"projects":["1U01CA244291-01"],"title":"Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant","recruitment_status":"Active, not recruiting","last_update_posted":"June 23, 2021"},"NCT02550327":{"publications":["32961746","34025067"],"projects":["1U54CA224083-01"],"title":"Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer","recruitment_status":"Completed","last_update_posted":"June 22, 2021"},"NCT03328078":{"publications":["32961746"],"projects":["1U54CA224083-01"],"title":"A Study of CA-4948 in Patients With Relapsed or Refractory Hematologic Malignancies","recruitment_status":"Recruiting","last_update_posted":"May 5, 2021"},"NCT04071366":{"publications":["32998963"],"projects":["1R01CA226983-01"],"title":"A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy","recruitment_status":"Recruiting","last_update_posted":"April 13, 2021"},"NCT03546361":{"publications":["33004476"],"projects":["1U2CCA233238-01"],"title":"CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer","recruitment_status":"Recruiting","last_update_posted":"July 8, 2021"},"NCT01560923":{"publications":["33005623"],"projects":["1U01CA224151-01"],"title":"Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer","recruitment_status":"Completed","last_update_posted":"April 3, 2020"},"NCT02073123":{"publications":["33005623"],"projects":["1U01CA224151-01"],"title":"Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma","recruitment_status":"Completed","last_update_posted":"June 5, 2020"},"NCT02835729":{"publications":["33005623"],"projects":["1U01CA224151-01"],"title":"A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia","recruitment_status":"Completed","last_update_posted":"June 4, 2020"},"NCT02052648":{"publications":["33005623"],"projects":["1U01CA224151-01"],"title":"Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors","recruitment_status":"Completed","last_update_posted":"May 28, 2020"},"NCT03301636":{"publications":["33005623"],"projects":["1U01CA224151-01"],"title":"A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma (NLG2107)","recruitment_status":"Terminated","last_update_posted":"June 5, 2020"},"NCT02502648":{"publications":["33005623"],"projects":["1U01CA224151-01"]},"NCT00720785":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Natural Killer Cells and Bortezomib to Treat Cancer","recruitment_status":"Completed","last_update_posted":"September 17, 2021"},"NCT02185781":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL)","recruitment_status":"Unknown","last_update_posted":"August 6, 2018"},"NCT02271711":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors","recruitment_status":"Completed","last_update_posted":"September 2, 2020"},"NCT02507154":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Reactivating NK Cells in Treating Refractory Head and Neck Cancer (NKEXPHNC)","recruitment_status":"Unknown","last_update_posted":"August 21, 2018"},"NCT02661685":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Safety Study of Adoptive Transfer of Autologous IKDC-like Cells","recruitment_status":"Completed","last_update_posted":"February 18, 2021"},"NCT03003728":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"July 10, 2020"},"NCT03410368":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"NK Cell-based Immunotherapy as Maintenance Therapy for Small-Cell Lung Cancer.","recruitment_status":"Unknown","last_update_posted":"July 17, 2018"},"NCT03415100":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients With Metastatic Solid Tumours","recruitment_status":"Unknown","last_update_posted":"August 1, 2018"},"NCT03499834":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"A Study to Evaluate the Safety and Efficacy of Ex Vivo Expanded Autologous Immune Killer Cells (IKC) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Target Therapy (IVY03)","recruitment_status":"Completed","last_update_posted":"April 16, 2020"},"NCT03592706":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy","recruitment_status":"Recruiting","last_update_posted":"April 16, 2020"},"NCT03662477":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Effect of NK Cell Immunotherapy on Advanced Lung Adenocarcinoma Adenocarcinoma With EGFR Mutation","recruitment_status":"Recruiting","last_update_posted":"December 6, 2019"},"NCT03941262":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy","recruitment_status":"Recruiting","last_update_posted":"May 3, 2021"},"NCT03958097":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"A Pilot Study of NK Cell Combined With PD-1 Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer","recruitment_status":"Unknown","last_update_posted":"May 21, 2019"},"NCT00900809":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"QUILT-3.018: Neukoplast&#8482; (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia","recruitment_status":"Completed","last_update_posted":"June 13, 2018"},"NCT00990717":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies","recruitment_status":"Completed","last_update_posted":"June 23, 2016"},"NCT01040026":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Expanded Natural Killer (NK) Cells for Multiple Myeloma Study","recruitment_status":"Active, not recruiting","last_update_posted":"November 15, 2019"},"NCT01729091":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma","recruitment_status":"Recruiting","last_update_posted":"July 14, 2021"},"NCT01807468":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors","recruitment_status":"Unknown","last_update_posted":"September 18, 2018"},"NCT02229266":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML (HINKL)","recruitment_status":"Terminated","last_update_posted":"August 16, 2021"},"NCT02409576":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas (NKEXPSARC)","recruitment_status":"Unknown","last_update_posted":"April 16, 2019"},"NCT02452697":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT (NK-DCI)","recruitment_status":"Recruiting","last_update_posted":"February 25, 2021"},"NCT02465957":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)","recruitment_status":"Active, not recruiting","last_update_posted":"August 14, 2020"},"NCT02727803":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma","recruitment_status":"Recruiting","last_update_posted":"August 7, 2020"},"NCT02742727":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma","recruitment_status":"Unknown","last_update_posted":"December 6, 2016"},"NCT02763475":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents","recruitment_status":"Completed","last_update_posted":"October 5, 2020"},"NCT02944162":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML","recruitment_status":"Unknown","last_update_posted":"December 6, 2016"},"NCT02955550":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)","recruitment_status":"Completed","last_update_posted":"July 22, 2020"},"NCT03019640":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma","recruitment_status":"Active, not recruiting","last_update_posted":"August 16, 2021"},"NCT03027128":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"QUILT-3.028: Study of haNK&#8482; for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors","recruitment_status":"Completed","last_update_posted":"August 28, 2019"},"NCT03068819":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant","recruitment_status":"Recruiting","last_update_posted":"September 20, 2021"},"NCT03136406":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy","recruitment_status":"Active, not recruiting","last_update_posted":"August 12, 2020"},"NCT03167164":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"March 19, 2021"},"NCT03167177":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"March 19, 2021"},"NCT03169738":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"March 19, 2021"},"NCT03169764":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"March 19, 2021"},"NCT03169777":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"March 18, 2021"},"NCT03169790":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"March 18, 2021"},"NCT03175666":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"March 18, 2021"},"NCT03197571":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"March 18, 2021"},"NCT03197584":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"March 18, 2021"},"NCT03300492":{"publications":["33007496"],"projects":["1U01CA239258-01"]},"NCT03329248":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy","recruitment_status":"Active, not recruiting","last_update_posted":"August 11, 2020"},"NCT03383978":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Intracranial Injection of NK-92/5.28.z Cells in Patients With Recurrent HER2-positive Glioblastoma (CAR2BRAIN)","recruitment_status":"Recruiting","last_update_posted":"September 25, 2020"},"NCT03387085":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.","recruitment_status":"Unknown","last_update_posted":"May 17, 2019"},"NCT03387098":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy","recruitment_status":"Unknown","last_update_posted":"July 16, 2019"},"NCT03387111":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed","recruitment_status":"Active, not recruiting","last_update_posted":"August 11, 2020"},"NCT03539406":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients (INTRO)","recruitment_status":"Unknown","last_update_posted":"September 16, 2019"},"NCT03554109":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine (TNBC)","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"May 14, 2019"},"NCT03563144":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"QUILT-3.088: NANT Pancreatic Cancer Vaccine","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"March 18, 2021"},"NCT03563157":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine","recruitment_status":"Active, not recruiting","last_update_posted":"September 18, 2020"},"NCT03563170":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"March 18, 2021"},"NCT03574649":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"August 28, 2019"},"NCT03586869":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"QUILT-3.080: NANT Pancreatic Cancer Vaccine","recruitment_status":"Unknown","last_update_posted":"July 16, 2019"},"NCT03647423":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"March 19, 2021"},"NCT03656705":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma","recruitment_status":"Enrolling by invitation","last_update_posted":"April 8, 2021"},"NCT03669172":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Efectiveness of Donor IL-15-stimulated NK Cells Post Transplant Infusion in in Acute Leukemia","recruitment_status":"Completed","last_update_posted":"September 5, 2021"},"NCT03778619":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin","recruitment_status":"Active, not recruiting","last_update_posted":"July 28, 2020"},"NCT03821519":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant (Haplo-CIK)","recruitment_status":"Recruiting","last_update_posted":"January 31, 2019"},"NCT03853317":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy","recruitment_status":"Recruiting","last_update_posted":"March 18, 2021"},"NCT03937895":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Allogeneic NK Cell (&quot;SMT-NK&quot;) in Combination With Pembrolizumab in Advanced Biliary Tract Cancer","recruitment_status":"Unknown","last_update_posted":"January 18, 2020"},"NCT03940833":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM","recruitment_status":"Recruiting","last_update_posted":"May 7, 2019"},"NCT04162158":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma","recruitment_status":"Recruiting","last_update_posted":"November 14, 2019"},"NCT04309084":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma","recruitment_status":"Recruiting","last_update_posted":"April 19, 2021"},"NCT04310592":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Natural Killer Cell (CYNK-001) Infusions in Adults With AML (CYNK001AML01)","recruitment_status":"Recruiting","last_update_posted":"March 2, 2021"},"NCT00625729":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia","recruitment_status":"Terminated","last_update_posted":"December 28, 2017"},"NCT00877110":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma","recruitment_status":"Completed","last_update_posted":"January 10, 2019"},"NCT01576692":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma","recruitment_status":"Completed","last_update_posted":"November 15, 2018"},"NCT02845999":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Allogenic Immunotherapy Based on Natural Killer (NK) Cell Adoptive Transfer in Metastatic Gastrointestinal Carcinoma Treated With Cetuximab (NK-EGFR01)","recruitment_status":"Completed","last_update_posted":"July 27, 2016"},"NCT03242603":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells (NKEXPGD2)","recruitment_status":"Unknown","last_update_posted":"March 30, 2018"},"NCT03554889":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells","recruitment_status":"Unknown","last_update_posted":"June 13, 2018"},"NCT04074746":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas","recruitment_status":"Recruiting","last_update_posted":"June 3, 2021"},"NCT04211675":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab (STING)","recruitment_status":"Not yet recruiting","last_update_posted":"April 1, 2021"},"NCT04245722":{"publications":["33007496"],"projects":["1U01CA239258-01"],"title":"FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies","recruitment_status":"Recruiting","last_update_posted":"August 10, 2021"},"NCT04106817":{"publications":["33044226"],"projects":["1U2CCA233195-01","1U2CCA233238-01"],"title":"Single Ascending Dose Challenge Study to Determine Safety and Reactogenicity of an Influenza Challenge Virus","recruitment_status":"Completed","last_update_posted":"January 14, 2020"},"NCT04514341":{"publications":["33121536"],"projects":["1UG3CA233229-01"],"title":"Implementing a Multilevel Intervention to Accelerate Colorectal Cancer Screening and Follow-up","recruitment_status":"Not yet recruiting","last_update_posted":"August 14, 2020"},"NCT02840058":{"publications":["33188038"],"projects":["2UM1CA154967-07"],"title":"Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1 (ITHER)","recruitment_status":"Recruiting","last_update_posted":"August 2, 2021"},"NCT04302675":{"publications":["33203635"],"projects":["1P50CA244688-01"],"title":"Adapting Motivational Interviewing for Maternal Immunizations (MI4MI) (MI4MI)","recruitment_status":"Active, not recruiting","last_update_posted":"July 26, 2021"},"NCT02066181":{"publications":["33258687"],"projects":["1U01CA233046-01"],"title":"Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis","recruitment_status":"Active, not recruiting","last_update_posted":"August 27, 2021"},"NCT03077477":{"publications":["33328226"],"projects":["1U01CA232488-01"],"title":"Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"June 14, 2018"},"NCT02369874":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer (EAGLE)","recruitment_status":"Completed","last_update_posted":"February 10, 2021"},"NCT00404339":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Vaccine Therapy in Treating Patients With Head and Neck Cancer","recruitment_status":"Completed","last_update_posted":"April 18, 2016"},"NCT00257738":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck","recruitment_status":"Completed","last_update_posted":"October 17, 2019"},"NCT02426892":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors","recruitment_status":"Active, not recruiting","last_update_posted":"February 17, 2020"},"NCT01147991":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer","recruitment_status":"Completed","last_update_posted":"February 28, 2012"},"NCT03821272":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients","recruitment_status":"Recruiting","last_update_posted":"May 13, 2021"},"NCT02002182":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"July 2, 2021"},"NCT02865135":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"September 9, 2021"},"NCT03260023":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers","recruitment_status":"Recruiting","last_update_posted":"June 29, 2021"},"NCT03418480":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"HPV Anti-CD40 RNA Vaccine (HARE-40)","recruitment_status":"Active, not recruiting","last_update_posted":"May 6, 2021"},"NCT04369937":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for &quot;Intermediate Risk&quot; HPV-16-associated Head and Neck Squamous Cell Carcinoma","recruitment_status":"Recruiting","last_update_posted":"September 20, 2021"},"NCT02544880":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC","recruitment_status":"Completed","last_update_posted":"June 15, 2021"},"NCT04247282":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection","recruitment_status":"Suspended\n                  \n      <!--","last_update_posted":"June 9, 2021"},"NCT02999646":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC","recruitment_status":"Recruiting","last_update_posted":"September 22, 2021"},"NCT03568058":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers","recruitment_status":"Active, not recruiting","last_update_posted":"December 9, 2020"},"NCT04266730":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (PANDA-VAC)","recruitment_status":"Not yet recruiting","last_update_posted":"July 8, 2021"},"NCT03689192":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors","recruitment_status":"Recruiting","last_update_posted":"February 12, 2020"},"NCT00019110":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer","recruitment_status":"Completed","last_update_posted":"April 29, 2015"},"NCT00019331":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors","recruitment_status":"Completed","last_update_posted":"June 20, 2013"},"NCT00021424":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer","recruitment_status":"Completed","last_update_posted":"April 30, 2015"},"NCT00027534":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer","recruitment_status":"Completed","last_update_posted":"September 8, 2014"},"NCT01462838":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Immune Therapy of HPV-induced Cancers","recruitment_status":"Completed","last_update_posted":"June 23, 2015"},"NCT01998542":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck (HNC)","recruitment_status":"Completed","last_update_posted":"January 23, 2020"},"NCT02163057":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma","recruitment_status":"Completed","last_update_posted":"January 22, 2021"},"NCT02291055":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head &amp; Neck Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"February 19, 2020"},"NCT02526316":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers (VICORYX-2)","recruitment_status":"Completed","last_update_posted":"July 2, 2017"},"NCT03162224":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent/Metastatic Head and Neck Cancer","recruitment_status":"Completed","last_update_posted":"April 27, 2021"},"NCT01684150":{"publications":["33371192"],"projects":["5R01CA176745-09"],"title":"A Phase 1, Open-Label, Dose-Escalation &amp; Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK &amp; PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving","recruitment_status":"Completed","last_update_posted":"August 4, 2016"},"NCT03701295":{"publications":["33371192"],"projects":["5R01CA176745-09"],"title":"Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement","recruitment_status":"Completed","last_update_posted":"September 9, 2021"},"NCT03724084":{"publications":["33371192"],"projects":["5R01CA176745-09"],"title":"Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement","recruitment_status":"Active, not recruiting","last_update_posted":"September 8, 2021"},"NCT04065399":{"publications":["33371192"],"projects":["5R01CA176745-09"],"title":"A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101)","recruitment_status":"Recruiting","last_update_posted":"May 6, 2021"},"NCT04067336":{"publications":["33371192"],"projects":["5R01CA176745-09"],"title":"First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia","recruitment_status":"Recruiting","last_update_posted":"August 24, 2021"},"NCT02698176":{"publications":["33371192"],"projects":["5R01CA176745-09"],"title":"A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)","recruitment_status":"Terminated","last_update_posted":"January 27, 2021"},"NCT02698189":{"publications":["33371192"],"projects":["5R01CA176745-09"],"title":"A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)","recruitment_status":"Active, not recruiting","last_update_posted":"July 13, 2021"},"NCT02308761":{"publications":["33371192"],"projects":["5R01CA176745-09"],"title":"A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome","recruitment_status":"Completed","last_update_posted":"December 11, 2017"},"NCT03068351":{"publications":["33371192"],"projects":["5R01CA176745-09"],"title":"Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma","recruitment_status":"Completed","last_update_posted":"February 7, 2020"},"NCT03292172":{"publications":["33371192"],"projects":["5R01CA176745-09"],"title":"A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer","recruitment_status":"Terminated","last_update_posted":"November 6, 2020"},"NCT03255096":{"publications":["33371192"],"projects":["5R01CA176745-09"],"title":"A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6","recruitment_status":"Completed","last_update_posted":"January 28, 2021"},"NCT03019003":{"publications":["33403469"],"projects":["1U01DE029188-01"],"title":"Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients","recruitment_status":"Recruiting","last_update_posted":"December 1, 2020"},"NCT03525795":{"publications":["33403469"],"projects":["1U01DE029188-01"],"title":"ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors","recruitment_status":"Completed","last_update_posted":"January 11, 2021"},"NCT03854474":{"publications":["33403469"],"projects":["1U01DE029188-01"],"title":"Tazemetostat and Pembrolizumab in Treating Patients With Locally Advanced or Metastatic Urothelial Carcinoma","recruitment_status":"Recruiting","last_update_posted":"September 20, 2021"},"NCT03065387":{"publications":["33414137"],"projects":["3U54CA224065-01S1"],"title":"Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation","recruitment_status":"Recruiting","last_update_posted":"January 25, 2021"},"NCT01693562":{"publications":["33420629"],"projects":["1U01CA233100-01"],"title":"A Phase 1/2 Study to Evaluate MEDI4736","recruitment_status":"Completed","last_update_posted":"May 13, 2021"},"NCT01970358":{"publications":["33479501"],"projects":["1U24CA224331-01"],"title":"A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma","recruitment_status":"Completed","last_update_posted":"December 9, 2020"},"NCT03125239":{"publications":["33527899"],"projects":["3R01CA204396-02S1"],"title":"Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia","recruitment_status":"Completed","last_update_posted":"June 30, 2020"},"NCT03465540":{"publications":["33560385"],"projects":["1U54CA224019-01"],"title":"Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies","recruitment_status":"Terminated","last_update_posted":"March 18, 2021"},"NCT03063632":{"publications":["33560388"],"projects":["2UM1CA154967-07"],"title":"Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and S&#233;zary Syndrome and Advanced Synovial Sarcoma","recruitment_status":"Active, not recruiting","last_update_posted":"May 14, 2021"},"NCT02595866":{"publications":["33608378"],"projects":["2UM1CA154967-07"],"title":"Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms","recruitment_status":"Recruiting","last_update_posted":"August 5, 2021"},"NCT01495598":{"publications":["33608378"],"projects":["2UM1CA154967-07"],"title":"Pomalidomide for Kaposi Sarcoma in People With or Without HIV","recruitment_status":"Active, not recruiting","last_update_posted":"September 21, 2021"},"NCT02659930":{"publications":["33608378"],"projects":["2UM1CA154967-07"],"title":"Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma","recruitment_status":"Recruiting","last_update_posted":"September 5, 2021"},"NCT00006518":{"publications":["33608378"],"projects":["2UM1CA154967-07"],"title":"Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer","recruitment_status":"Recruiting","last_update_posted":"September 23, 2021"},"NCT00092222":{"publications":["33608378"],"projects":["2UM1CA154967-07"],"title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","recruitment_status":"Recruiting","last_update_posted":"September 21, 2021"},"NCT01419561":{"publications":["33608378"],"projects":["2UM1CA154967-07"],"title":"History of the KSHV Inflammatory Cytokine Syndrome (KICS)","recruitment_status":"Recruiting","last_update_posted":"September 14, 2021"},"NCT00983424":{"publications":["33626321"],"projects":["3U54CA224065-01S1"],"title":"Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer","recruitment_status":"Completed","last_update_posted":"September 16, 2013"},"NCT02188264":{"publications":["33626321"],"projects":["3U54CA224065-01S1"],"title":"Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"April 2, 2021"},"NCT00003950":{"publications":["33626321"],"projects":["3U54CA224065-01S1"],"title":"Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer","recruitment_status":"Completed","last_update_posted":"March 7, 2014"},"NCT01391143":{"publications":["33658518"],"projects":["1U54CA224079-01"],"title":"Safety Study of MGA271 in Refractory Cancer","recruitment_status":"Completed","last_update_posted":"January 10, 2020"},"NCT04129320":{"publications":["33658518"],"projects":["1U54CA224079-01"],"title":"Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"October 14, 2020"},"NCT01942837":{"publications":["33664492"],"projects":["1U01CA233100-01"],"title":"Phase II Trial of Enzalutamide for CRPC With Correlative Assessment of Androgen Receptor Signaling","recruitment_status":"Active, not recruiting","last_update_posted":"January 12, 2021"},"NCT01924689":{"publications":["33669386"],"projects":["1UG3CA244687-01"],"title":"Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies","recruitment_status":"Completed","last_update_posted":"September 9, 2019"},"NCT02807805":{"publications":["33737681"],"projects":["1U54CA233306-01"],"title":"Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer","recruitment_status":"Recruiting","last_update_posted":"March 19, 2021"},"NCT00309933":{"publications":["33749062"],"projects":["3UG1CA189828-07S1"],"title":"Quality of Life in Female Breast Cancer Survivors and Their Spouse, Partner, or Acquaintance","recruitment_status":"Active, not recruiting","last_update_posted":"February 3, 2021"},"NCT03710603":{"publications":["33777050"],"projects":["1U01CA244291-01"],"title":"Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma (Perseus)","recruitment_status":"Active, not recruiting","last_update_posted":"August 26, 2021"},"NCT02703623":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"November 12, 2020"},"NCT01688492":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-na&#239;ve Patients With Progressive Metastatic Castration-resistant Prostate Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"September 10, 2021"},"NCT04388852":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers","recruitment_status":"Recruiting","last_update_posted":"June 29, 2021"},"NCT02787005":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)","recruitment_status":"Active, not recruiting","last_update_posted":"August 23, 2021"},"NCT03834493":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)","recruitment_status":"Recruiting","last_update_posted":"September 16, 2021"},"NCT02312557":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide","recruitment_status":"Active, not recruiting","last_update_posted":"May 17, 2021"},"NCT03770455":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC","recruitment_status":"Active, not recruiting","last_update_posted":"October 19, 2020"},"NCT03338790":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CheckMate 9KD)","recruitment_status":"Active, not recruiting","last_update_posted":"August 30, 2021"},"NCT02861573":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","recruitment_status":"Recruiting","last_update_posted":"September 16, 2021"},"NCT03658447":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr) (PRINCE)","recruitment_status":"Active, not recruiting","last_update_posted":"December 23, 2020"},"NCT03093428":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC","recruitment_status":"Active, not recruiting","last_update_posted":"July 28, 2021"},"NCT03834506":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-na&#239;ve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)","recruitment_status":"Active, not recruiting","last_update_posted":"June 9, 2021"},"NCT03248570":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects","recruitment_status":"Recruiting","last_update_posted":"May 26, 2021"},"NCT02998567":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Combination Study of Guadecitabine and Pembrolizumab. (HyPeR)","recruitment_status":"Active, not recruiting","last_update_posted":"November 17, 2020"},"NCT03582475":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate","recruitment_status":"Recruiting","last_update_posted":"July 14, 2021"},"NCT03572478":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer","recruitment_status":"Terminated","last_update_posted":"March 9, 2021"},"NCT03834519":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (KEYLYNK-010)","recruitment_status":"Active, not recruiting","last_update_posted":"September 16, 2021"},"NCT02484404":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers","recruitment_status":"Recruiting","last_update_posted":"September 20, 2021"},"NCT03330405":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors","recruitment_status":"Active, not recruiting","last_update_posted":"September 8, 2021"},"NCT04446117":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02)","recruitment_status":"Recruiting","last_update_posted":"September 17, 2021"},"NCT03849469":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"A Study of XmAb&#174;22841 Monotherapy &amp; in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4)","recruitment_status":"Recruiting","last_update_posted":"August 18, 2021"},"NCT03406858":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Pembrolizumab and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer","recruitment_status":"Recruiting","last_update_posted":"March 1, 2021"},"NCT03217747":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies","recruitment_status":"Recruiting","last_update_posted":"October 30, 2020"},"NCT03821246":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Atezolizumab With or Without Tocilizumab in Treating Men With Prostate Cancer Before Radical Prostatectomy","recruitment_status":"Recruiting","last_update_posted":"November 12, 2020"},"NCT03473925":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)","recruitment_status":"Completed","last_update_posted":"July 2, 2021"},"NCT04020094":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer (AtezoVax)","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"September 22, 2021"},"NCT03835533":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (PORTER)","recruitment_status":"Recruiting","last_update_posted":"August 3, 2021"},"NCT04090775":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma","recruitment_status":"Recruiting","last_update_posted":"October 11, 2019"},"NCT03518606":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours (MOVIE)","recruitment_status":"Active, not recruiting","last_update_posted":"September 16, 2021"},"NCT03532217":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"September 17, 2021"},"NCT03204812":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer","recruitment_status":"Completed","last_update_posted":"April 15, 2021"},"NCT02985957":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Study of Nivolumab Plus Ipilimumab, Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)","recruitment_status":"Recruiting","last_update_posted":"April 23, 2021"},"NCT03879122":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"September 22, 2021"},"NCT03866382":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","recruitment_status":"Recruiting","last_update_posted":"September 20, 2021"},"NCT03454451":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers","recruitment_status":"Recruiting","last_update_posted":"July 27, 2021"},"NCT02655822":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers","recruitment_status":"Completed","last_update_posted":"August 30, 2021"},"NCT04089553":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"August 3, 2021"},"NCT02740985":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies","recruitment_status":"Active, not recruiting","last_update_posted":"July 30, 2021"},"NCT04381832":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer (ARC-6)","recruitment_status":"Recruiting","last_update_posted":"July 28, 2021"},"NCT03792841":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With mCRPC","recruitment_status":"Recruiting","last_update_posted":"June 7, 2021"},"NCT04631601":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)","recruitment_status":"Recruiting","last_update_posted":"September 22, 2021"},"NCT03972657":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer","recruitment_status":"Recruiting","last_update_posted":"July 12, 2021"},"NCT04702737":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer","recruitment_status":"Recruiting","last_update_posted":"September 10, 2021"},"NCT04221542":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer","recruitment_status":"Recruiting","last_update_posted":"September 2, 2021"},"NCT03577028":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Study of HPN424 in Patients With Advanced Prostate Cancer","recruitment_status":"Recruiting","last_update_posted":"October 5, 2020"},"NCT04397276":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors","recruitment_status":"Recruiting","last_update_posted":"September 10, 2021"},"NCT03873805":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer","recruitment_status":"Recruiting","last_update_posted":"March 10, 2021"},"NCT03753243":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer","recruitment_status":"Recruiting","last_update_posted":"September 23, 2020"},"NCT03810105":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"A Study of Olaparib and Durvalumab in Prostate Cancer","recruitment_status":"Recruiting","last_update_posted":"September 16, 2021"},"NCT03016312":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen (IMbassador250)","recruitment_status":"Active, not recruiting","last_update_posted":"August 19, 2021"},"NCT04131413":{"publications":["33842408"],"projects":["1U01CA233056-01","1U01CA233097-01"],"title":"HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia","recruitment_status":"Recruiting","last_update_posted":"July 6, 2021"},"NCT01440088":{"publications":["33859749"],"projects":["3R01CA187532-03S1"],"title":"A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma","recruitment_status":"Completed","last_update_posted":"June 2, 2016"},"NCT01746979":{"publications":["33859749"],"projects":["3R01CA187532-03S1"],"title":"Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma (MAESTRO)","recruitment_status":"Completed","last_update_posted":"December 2, 2017"},"NCT02267603":{"publications":["33879601"],"projects":["2UM1CA154967-07"],"title":"Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"March 22, 2021"},"NCT03747484":{"publications":["33879601"],"projects":["2UM1CA154967-07"],"title":"Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer","recruitment_status":"Recruiting","last_update_posted":"July 8, 2021"},"NCT02014909":{"publications":["33888713"],"projects":["1U01DE028227-01"],"title":"A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors","recruitment_status":"Completed","last_update_posted":"July 24, 2017"},"NCT03254927":{"publications":["33888713"],"projects":["1U01DE028227-01"],"title":"A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma","recruitment_status":"Completed","last_update_posted":"April 28, 2021"},"NCT03338972":{"publications":["33914708"],"projects":["1U01CA247548-01"],"title":"Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma","recruitment_status":"Active, not recruiting","last_update_posted":"June 10, 2021"},"NCT03684889":{"publications":["33914708"],"projects":["1U01CA247548-01"],"title":"CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma","recruitment_status":"Active, not recruiting","last_update_posted":"February 10, 2021"},"NCT01865617":{"publications":["33914708"],"projects":["1U01CA247548-01"],"title":"Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia","recruitment_status":"Completed","last_update_posted":"July 20, 2021"},"NCT03103971":{"publications":["33914708"],"projects":["1U01CA247548-01"],"title":"huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia","recruitment_status":"Recruiting","last_update_posted":"September 10, 2021"},"NCT02706405":{"publications":["33914708"],"projects":["1U01CA247548-01"],"title":"JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","recruitment_status":"Active, not recruiting","last_update_posted":"July 16, 2021"},"NCT02631044":{"publications":["33914708"],"projects":["1U01CA247548-01"],"title":"Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)","recruitment_status":"Recruiting","last_update_posted":"June 21, 2021"},"NCT03277729":{"publications":["33914708"],"projects":["1U01CA247548-01"],"title":"A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas","recruitment_status":"Recruiting","last_update_posted":"July 13, 2021"},"NCT03105336":{"publications":["33914708"],"projects":["1U01CA247548-01"],"title":"A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5)","recruitment_status":"Active, not recruiting","last_update_posted":"August 5, 2021"},"NCT02614066":{"publications":["33914708"],"projects":["1U01CA247548-01"],"title":"A Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3) (ZUMA-3)","recruitment_status":"Active, not recruiting","last_update_posted":"June 28, 2021"},"NCT03331198":{"publications":["33914708"],"projects":["1U01CA247548-01"],"title":"Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)","recruitment_status":"Recruiting","last_update_posted":"May 7, 2021"},"NCT03575351":{"publications":["33914708"],"projects":["1U01CA247548-01"],"title":"A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM)","recruitment_status":"Active, not recruiting","last_update_posted":"June 10, 2021"},"NCT02504372":{"publications":["33937052"],"projects":["1U01CA233102-01"],"title":"Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) (PEARLS)","recruitment_status":"Active, not recruiting","last_update_posted":"July 17, 2020"},"NCT02998528":{"publications":["33937052"],"projects":["1U01CA233102-01"],"title":"A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816)","recruitment_status":"Active, not recruiting","last_update_posted":"August 26, 2020"},"NCT04025879":{"publications":["33937052"],"projects":["1U01CA233102-01"],"title":"A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer","recruitment_status":"Recruiting","last_update_posted":"September 21, 2021"},"NCT04214262":{"publications":["33937052"],"projects":["1U01CA233102-01"],"title":"Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer","recruitment_status":"Recruiting","last_update_posted":"September 21, 2021"},"NCT02884102":{"publications":["33963182"],"projects":["1U2CCA233303-01"],"title":"MMRF Molecular Profiling Protocol","recruitment_status":"Recruiting","last_update_posted":"March 19, 2019"},"NCT01239134":{"publications":["33976133"],"projects":["1U01CA224348-01","1U2CCA233262-01"],"title":"Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001)","recruitment_status":"Completed","last_update_posted":"August 14, 2019"},"NCT04021043":{"publications":["33976133"],"projects":["1U01CA224348-01","1U2CCA233262-01"],"title":"BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers","recruitment_status":"Recruiting","last_update_posted":"January 14, 2021"},"NCT02740270":{"publications":["33976133"],"projects":["1U01CA224348-01","1U2CCA233262-01"],"title":"Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas","recruitment_status":"Completed","last_update_posted":"February 21, 2021"},"NCT02628574":{"publications":["33976133"],"projects":["1U01CA224348-01","1U2CCA233262-01"],"title":"Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab","recruitment_status":"Completed","last_update_posted":"October 26, 2020"},"NCT02598960":{"publications":["33976133"],"projects":["1U01CA224348-01","1U2CCA233262-01"],"title":"An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.","recruitment_status":"Completed","last_update_posted":"December 21, 2020"},"NCT04225039":{"publications":["33976133"],"projects":["1U01CA224348-01","1U2CCA233262-01"],"title":"Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma","recruitment_status":"Recruiting","last_update_posted":"February 5, 2021"},"NCT02617589":{"publications":["33976133"],"projects":["1U01CA224348-01","1U2CCA233262-01"]},"NCT01804465":{"publications":["33986125"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer","recruitment_status":"Completed","last_update_posted":"August 18, 2021"},"NCT04427527":{"publications":["34011410"],"projects":["1UG3CA233282-01"],"title":"Accelerating Colorectal Cancer Screening Through Implementation Science in Appalachia (ACCSIS)","recruitment_status":"Recruiting","last_update_posted":"May 3, 2021"},"NCT01383538":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma","recruitment_status":"Completed","last_update_posted":"August 8, 2017"},"NCT01195415":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer","recruitment_status":"Completed","last_update_posted":"August 7, 2017"},"NCT01064622":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer","recruitment_status":"Completed","last_update_posted":"August 14, 2015"},"NCT01088815":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas","recruitment_status":"Completed","last_update_posted":"April 26, 2019"},"NCT01487785":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients","recruitment_status":"Completed","last_update_posted":"December 19, 2020"},"NCT02358161":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer (MATRIX)","recruitment_status":"Completed","last_update_posted":"January 9, 2020"},"NCT01373164":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer","recruitment_status":"Completed","last_update_posted":"May 16, 2018"},"NCT02734160":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer","recruitment_status":"Completed","last_update_posted":"August 5, 2019"},"NCT01821729":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"September 25, 2020"},"NCT03563248":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer","recruitment_status":"Recruiting","last_update_posted":"January 20, 2021"},"NCT03941093":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Locally Advanced Pancreatic Cancer","recruitment_status":"Recruiting","last_update_posted":"September 17, 2021"},"NCT04054362":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PINBALL)","recruitment_status":"Unknown","last_update_posted":"December 16, 2019"},"NCT04524702":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced or Metastatic Pancreatic Cancer","recruitment_status":"Recruiting","last_update_posted":"February 21, 2021"},"NCT03883919":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy","recruitment_status":"Active, not recruiting","last_update_posted":"May 18, 2021"},"NCT03331562":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"A SU2C Catalyst&#174; Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer","recruitment_status":"Completed","last_update_posted":"October 8, 2020"},"NCT03307148":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"Stromal TARgeting for PAncreatic Cancer (STAR_PAC) (STAR_PAC)","recruitment_status":"Completed","last_update_posted":"January 22, 2020"},"NCT02715804":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma","recruitment_status":"Terminated","last_update_posted":"July 14, 2020"},"NCT01959139":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"January 5, 2021"},"NCT01472198":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma","recruitment_status":"Completed","last_update_posted":"March 10, 2015"},"NCT03348514":{"publications":["34059639"],"projects":["3P30CA168524-09S3"],"title":"Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors","recruitment_status":"Recruiting","last_update_posted":"September 1, 2020"},"NCT04608045":{"publications":["34059639"],"projects":["3P30CA168524-09S3"],"title":"Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors","recruitment_status":"Recruiting","last_update_posted":"October 30, 2020"},"NCT04525131":{"publications":["34059639"],"projects":["3P30CA168524-09S3"],"title":"Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors","recruitment_status":"Recruiting","last_update_posted":"December 19, 2020"},"NCT03985852":{"publications":["34078380"],"projects":["1U01CA232826-01"],"title":"Broadening the Reach, Impact, and Delivery of Genetic Services (BRIDGE)","recruitment_status":"Enrolling by invitation","last_update_posted":"August 27, 2021"},"NCT01836276":{"publications":["34084252"],"projects":["3P30CA168524-09S3"],"title":"Understanding Disparities in Quitting in African American and White Smokers","recruitment_status":"Completed","last_update_posted":"October 24, 2018"},"NCT02588443":{"publications":["34101617","34296197"],"projects":["1U01CA224193-01","1U01CA224145-01"],"title":"Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma","recruitment_status":"Completed","last_update_posted":"April 16, 2019"},"NCT04106219":{"publications":["34107377"],"projects":["3P30CA082103-21S9","3P30CA082103-21S6"],"title":"A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma","recruitment_status":"Recruiting","last_update_posted":"August 18, 2021"},"NCT04365257":{"publications":["34114951"],"projects":["1U01CA247576-01"],"title":"Prazosin to Prevent COVID-19 (PREVENT-COVID Trial) (PREVENT)","recruitment_status":"Recruiting","last_update_posted":"June 9, 2021"},"NCT02306954":{"publications":["34172518"],"projects":["1U54CA232568-01"],"title":"Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer","recruitment_status":"Recruiting","last_update_posted":"March 3, 2020"},"NCT03607617":{"publications":["34174834"],"projects":["1P50CA244289-01"],"title":"ASCEND: ApproacheS to CHC ImplEmeNtation of SDH Data Collection and Action (ASCEND)","recruitment_status":"Active, not recruiting","last_update_posted":"June 15, 2021"},"NCT00546156":{"publications":["34188163"],"projects":["1U01CA224348-01"],"title":"Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer","recruitment_status":"Completed","last_update_posted":"May 18, 2021"},"NCT02723994":{"publications":["34210682"],"projects":["1U01CA232486-01"],"title":"A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia","recruitment_status":"Recruiting","last_update_posted":"September 22, 2021"},"NCT02883049":{"publications":["34210682"],"projects":["1U01CA232486-01"],"title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","recruitment_status":"Active, not recruiting","last_update_posted":"September 8, 2021"},"NCT02186821":{"publications":["34242968"],"projects":["3P30CA168524-09S3"],"title":"Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) (SIGNATURE)","recruitment_status":"Terminated","last_update_posted":"April 8, 2021"},"NCT00291096":{"publications":["34244155"],"projects":["3P30CA168524-09S3"],"title":"Protocol for Women at Increased Risk of Developing Breast Cancer","recruitment_status":"Recruiting","last_update_posted":"December 31, 2020"},"NCT02101970":{"publications":["34244155"],"projects":["3P30CA168524-09S3"],"title":"Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women","recruitment_status":"Completed","last_update_posted":"February 6, 2019"},"NCT01749969":{"publications":["34272304"],"projects":["3P30CA082103-21S9","3P30CA082103-21S6"],"title":"SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients","recruitment_status":"Active, not recruiting","last_update_posted":"September 21, 2021"},"NCT03233854":{"publications":["34312556"],"projects":["1U54CA232568-01"],"title":"CD19/CD22 Chimeric Antigen Receptor(CAR) T Cells in Adults With Recurrent/Refractory B Cell Malignancies","recruitment_status":"Recruiting","last_update_posted":"August 17, 2021"},"NCT04088890":{"publications":["34312556"],"projects":["1U54CA232568-01"],"title":"Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies","recruitment_status":"Recruiting","last_update_posted":"August 3, 2021"},"NCT02328677":{"publications":["34359718"],"projects":["3P30CA042014-31S5"],"title":"ColoCare Study - Colorectal Cancer Cohort","recruitment_status":"Recruiting","last_update_posted":"October 19, 2020"},"NCT04485130":{"publications":["34401873"],"projects":["3P30CA006516-55S9"],"title":"DISulfiram for COvid-19 (DISCO) Trial (DISCO)","recruitment_status":"Recruiting","last_update_posted":"May 10, 2021"},"NCT04594343":{"publications":["34401873"],"projects":["3P30CA006516-55S9"],"title":"Clinical Study to Evaluate the Effects of Disulfiram in Patients With Moderate COVID-19","recruitment_status":"Active, not recruiting","last_update_posted":"September 1, 2021"},"NCT04381936":{"publications":["34401873"],"projects":["3P30CA006516-55S9"],"title":"Randomised Evaluation of COVID-19 Therapy (RECOVERY)","recruitment_status":"Recruiting","last_update_posted":"July 30, 2021"},"NCT01971515":{"publications":["34407844"],"projects":["3P30CA054174-25S2","3P30CA054174-25S1"],"title":"First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies","recruitment_status":"Completed","last_update_posted":"September 19, 2018"},"NCT03161431":{"publications":["34408137"],"projects":["3P30CA046592-31S8","3P30CA046592-31S4"],"title":"SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab","recruitment_status":"Recruiting","last_update_posted":"September 23, 2021"},"NCT02054104":{"publications":["34430349"],"projects":["1U24CA224319-01","1U01DK124165-01"],"title":"Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum","recruitment_status":"Terminated","last_update_posted":"May 20, 2021"},"NCT04874831":{"publications":["34439353"],"projects":["3P30CA042014-31S5"],"title":"Domatinostat in Combination With Avelumab in Patients With Treatment-na&#239;ve Metastatic Merkel Cell Carcinoma (MERKLIN 1)","recruitment_status":"Not yet recruiting","last_update_posted":"July 6, 2021"},"NCT04393753":{"publications":["34439353"],"projects":["3P30CA042014-31S5"],"title":"Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 (MERKLIN2)","recruitment_status":"Recruiting","last_update_posted":"June 29, 2021"},"NCT04871594":{"publications":["34439353"],"projects":["3P30CA042014-31S5"],"title":"Checkpoint Inhibition With or Without Domatinostat in Urothelial Cancer (TURANDOT)","recruitment_status":"Recruiting","last_update_posted":"September 1, 2021"},"NCT04133948":{"publications":["34439353"],"projects":["3P30CA042014-31S5"],"title":"Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma (DONIMI)","recruitment_status":"Recruiting","last_update_posted":"June 1, 2020"},"NCT03812796":{"publications":["34439353"],"projects":["3P30CA042014-31S5"],"title":"Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE) (EMERGE)","recruitment_status":"Recruiting","last_update_posted":"February 5, 2019"},"NCT02261480":{"publications":["34451986"],"projects":["3P30CA021765-41S3"],"title":"A New Reagent Assay Examining Natural Parvovirus B19 Infection in Sickle Cell Disease","recruitment_status":"Completed","last_update_posted":"September 19, 2016"},"NCT01881867":{"publications":["34452927"],"projects":["1U24CA224309-01","2UM1CA154967-07"],"title":"CYT107 After Vaccine Treatment (Provenge&#174;) in Patients With Metastatic Castration-Resistant Prostate Cancer","recruitment_status":"Completed","last_update_posted":"July 9, 2019"},"NCT00065442":{"publications":["34452927"],"projects":["1U24CA224309-01","2UM1CA154967-07"],"title":"Provenge&#174; (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy","recruitment_status":"Completed","last_update_posted":"September 6, 2010"},"NCT04317040":{"publications":["34462760"],"projects":["3P30CA016058-44S3"],"title":"CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007) (SAC-COVID)","recruitment_status":"Completed","last_update_posted":"July 22, 2021"},"NCT04315948":{"publications":["34462760"],"projects":["3P30CA016058-44S3"],"title":"Trial of Treatments for COVID-19 in Hospitalized Adults (DisCoVeRy)","recruitment_status":"Recruiting","last_update_posted":"September 16, 2021"},"NCT03109661":{"publications":["34488832"],"projects":["3P30CA177558-08S2"]},"NCT03109561":{"publications":["34488832"],"projects":["3P30CA177558-08S2"],"title":"Apolipoprotein E (ApoE) and Metabolism","recruitment_status":"Completed","last_update_posted":"July 23, 2020"},"NCT03451383":{"publications":["34515905"],"projects":["3P30CA008748-54S3"],"title":"Older Breast Cancer Patients: Risk for Cognitive Decline (TLC)","recruitment_status":"Recruiting","last_update_posted":"July 30, 2021"},"NCT00999609":{"publications":["34532415"],"projects":["3P30CA013696-45S1"],"title":"Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis","recruitment_status":"Active, not recruiting","last_update_posted":"May 18, 2020"},"NCT02610582":{"publications":["34532415"],"projects":["3P30CA013696-45S1"],"title":"Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked Achromatopsia (Colourbridge)","recruitment_status":"Recruiting","last_update_posted":"April 1, 2021"},"NCT03278873":{"publications":["34532415"],"projects":["3P30CA013696-45S1"],"title":"Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3","recruitment_status":"Recruiting","last_update_posted":"March 24, 2021"},"NCT03758404":{"publications":["34532415"],"projects":["3P30CA013696-45S1"],"title":"Gene Therapy for Achromatopsia (CNGA3) (CNGA3)","recruitment_status":"Completed","last_update_posted":"June 25, 2021"},"NCT02935517":{"publications":["34532415"],"projects":["3P30CA013696-45S1"],"title":"Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia","recruitment_status":"Recruiting","last_update_posted":"April 6, 2021"},"NCT02599922":{"publications":["34532415"],"projects":["3P30CA013696-45S1"],"title":"Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia","recruitment_status":"Recruiting","last_update_posted":"April 6, 2021"},"NCT01461213":{"publications":["34532415"],"projects":["3P30CA013696-45S1"],"title":"Gene Therapy for Blindness Caused by Choroideremia","recruitment_status":"Completed","last_update_posted":"November 17, 2017"},"NCT02553135":{"publications":["34532415"],"projects":["3P30CA013696-45S1"],"title":"Choroideremia Gene Therapy Clinical Trial","recruitment_status":"Completed","last_update_posted":"July 29, 2019"},"NCT02671539":{"publications":["34532415"],"projects":["3P30CA013696-45S1"],"title":"THOR - T&#252;bingen Choroideremia Gene Therapy Trial (THOR)","recruitment_status":"Completed","last_update_posted":"October 27, 2020"},"NCT03496012":{"publications":["34532415"],"projects":["3P30CA013696-45S1"],"title":"Efficacy and Safety of BIIB111 for the Treatment of Choroideremia (STAR)","recruitment_status":"Completed","last_update_posted":"December 23, 2020"},"NCT01367444":{"publications":["34532415"],"projects":["3P30CA013696-45S1"],"title":"Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular Degeneration","recruitment_status":"Terminated","last_update_posted":"June 5, 2020"},"NCT01736592":{"publications":["34532415"],"projects":["3P30CA013696-45S1"],"title":"Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration","recruitment_status":"Active, not recruiting","last_update_posted":"August 11, 2020"},"NCT02065011":{"publications":["34532415"],"projects":["3P30CA013696-45S1"],"title":"A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B","recruitment_status":"Active, not recruiting","last_update_posted":"August 11, 2020"},"NCT01505062":{"publications":["34532415"],"projects":["3P30CA013696-45S1"],"title":"Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B","recruitment_status":"Terminated","last_update_posted":"March 18, 2020"},"NCT03116113":{"publications":["34532415"],"projects":["3P30CA013696-45S1"],"title":"A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112 (XIRIUS)","recruitment_status":"Completed","last_update_posted":"May 18, 2021"},"NCT03316560":{"publications":["34532415"],"projects":["3P30CA013696-45S1"],"title":"Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations","recruitment_status":"Recruiting","last_update_posted":"July 15, 2021"},"NCT03252847":{"publications":["34532415"],"projects":["3P30CA013696-45S1"],"title":"Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) Retinitis Pigmentosa GTPase Regulator (RPGR)","recruitment_status":"Active, not recruiting","last_update_posted":"March 13, 2020"},"NCT01482195":{"publications":["34532415"],"projects":["3P30CA013696-45S1"],"title":"Trial of Subretinal Injection of (rAAV2-VMD2-hMERTK)","recruitment_status":"Completed","last_update_posted":"July 15, 2021"},"NCT03374657":{"publications":["34532415"],"projects":["3P30CA013696-45S1"],"title":"A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa","recruitment_status":"Recruiting","last_update_posted":"March 19, 2021"},"NCT03328130":{"publications":["34532415"],"projects":["3P30CA013696-45S1"],"title":"Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene","recruitment_status":"Recruiting","last_update_posted":"March 18, 2021"},"NCT01267422":{"publications":["34532415"],"projects":["3P30CA013696-45S1"],"title":"Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON) (rAAV2-ND4)","recruitment_status":"Completed","last_update_posted":"January 31, 2018"},"NCT03153293":{"publications":["34532415"],"projects":["3P30CA013696-45S1"],"title":"A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy","recruitment_status":"Active, not recruiting","last_update_posted":"September 17, 2020"},"NCT02161380":{"publications":["34532415"],"projects":["3P30CA013696-45S1"],"title":"Safety Study of an Adeno-associated Virus Vector for Gene Therapy of Leber's Hereditary Optic Neuropathy (LHON)","recruitment_status":"Active, not recruiting","last_update_posted":"July 6, 2021"},"NCT02652767":{"publications":["34532415"],"projects":["3P30CA013696-45S1"],"title":"Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation (RESCUE)","recruitment_status":"Completed","last_update_posted":"January 28, 2020"},"NCT02652780":{"publications":["34532415"],"projects":["3P30CA013696-45S1"],"title":"Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE) (REVERSE)","recruitment_status":"Completed","last_update_posted":"January 23, 2020"},"NCT03293524":{"publications":["34532415"],"projects":["3P30CA013696-45S1"],"title":"Efficacy &amp; Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year (REFLECT)","recruitment_status":"Active, not recruiting","last_update_posted":"February 8, 2021"},"NCT02317887":{"publications":["34532415"],"projects":["3P30CA013696-45S1"],"title":"Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis","recruitment_status":"Recruiting","last_update_posted":"May 3, 2021"},"NCT02416622":{"publications":["34532415"],"projects":["3P30CA013696-45S1"],"title":"Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)","recruitment_status":"Active, not recruiting","last_update_posted":"July 14, 2020"},"NCT04131062":{"title":"Trial to Compare eConsent With Standard Consent Among Prospective Biobank Participants","recruitment_status":"","last_update_posted":"January 22, 2021","publications":[],"projects":["1R01CA211723-01A1"]},"NCT03698162":{"title":"Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases","recruitment_status":"","last_update_posted":"April 5, 2021","publications":[],"projects":["1R33CA225400-01"]},"NCT01946789":{"title":"A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors","recruitment_status":"","last_update_posted":"April 17, 2019","publications":[],"projects":["2UM1CA154967-07"]},"NCT01961115":{"title":"Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma","recruitment_status":"Completed","last_update_posted":"June 8, 2018","publications":[],"projects":["2UM1CA154967-07"]},"NCT04751383":{"title":"Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma","recruitment_status":"","last_update_posted":"August 30, 2021","publications":[],"projects":["2UM1CA154967-07"]},"NCT04500548":{"title":"Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study","recruitment_status":"","last_update_posted":"August 26, 2021","publications":[],"projects":["2UM1CA154967-07"]},"NCT03513952":{"title":"Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma","recruitment_status":"","last_update_posted":"September 14, 2021","publications":[],"projects":["2UM1CA154967-07"]},"NCT01727076":{"title":"Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer","recruitment_status":"","last_update_posted":"September 15, 2017","publications":[],"projects":["2UM1CA154967-07"]},"NCT04410302":{"title":"Patient-Derived Xenografts to Reduce Cancer Health Disparities","recruitment_status":"","last_update_posted":"July 13, 2021","publications":[],"projects":["1U54CA233306-01"]},"NCT04406714":{"title":"Scaling CRC Screening Through Outreach, Referral, and Engagement (SCORE)","recruitment_status":"","last_update_posted":"May 12, 2021","publications":[],"projects":["1UG3CA233251-01"]},"NCT03892967":{"title":"Enhanced, EHR-facilitated Cancer Symptom Control (E2C2) Pragmatic Clinical Trial","recruitment_status":"","last_update_posted":"August 13, 2021","publications":[],"projects":["1UM1CA233033-01"]},"NCT03988543":{"title":"Bilingual Electronic Symptom Management Program Across Multi-site, Comprehensive Cancer Center","recruitment_status":"","last_update_posted":"March 3, 2021","publications":[],"projects":["1UM1CA233035-01"]},"NCT03850912":{"title":"Symptom Management Implementation of Patient Reported Outcomes in Oncology","recruitment_status":"","last_update_posted":"September 16, 2020","publications":[],"projects":["1UM1CA233080-01"]},"NCT04199026":{"title":"Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma","recruitment_status":"","last_update_posted":"March 6, 2020","publications":[],"projects":["3R01CA180279-05S1"]},"NCT03538938":{"title":"Improving Quitline Support Study","recruitment_status":"","last_update_posted":"May 17, 2021","publications":[],"projects":["5R01CA218156-02"]},"NCT04314284":{"title":"Patient-Centered Intervention to Reduce Cancer Patients&apos; Financial Toxicity","recruitment_status":"","last_update_posted":"January 14, 2021","publications":[],"projects":["1P50CA244431-01"]},"NCT04585919":{"title":"Paired Promotion of Colorectal Cancer and Social Determinants of Health Screening","recruitment_status":"","last_update_posted":"April 1, 2021","publications":[],"projects":["1P50CA244433-01"]},"NCT05021133":{"title":"Tele-Navigation of Lung Cancer Screening (Tele-Navi LCS)","recruitment_status":"Not yet recruiting","last_update_posted":"August 31, 2021","publications":[],"projects":["1P50CA244693-01"]},"NCT04337203":{"title":"Shared Healthcare Actions and Reflections Electronic Systems in Survivorship","recruitment_status":"","last_update_posted":"June 18, 2021","publications":[],"projects":["1P50CA244693-01"]},"NCT04746794":{"title":"Early Detection of GEnetic Risk (EDGE)","recruitment_status":"","last_update_posted":"February 10, 2021","publications":[],"projects":["1U01CA232795-01A1"]},"NCT04323774":{"title":"Intervention For AYAS With Cancer Risk Syndromes","recruitment_status":"","last_update_posted":"April 13, 2021","publications":[],"projects":["1U01CA243688-01"]},"NCT04939597":{"title":"A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor","recruitment_status":"","last_update_posted":"June 25, 2021","publications":[],"projects":["1U01CA246568-01"]},"NCT04789720":{"title":"Using Information Technology to Improve Outcomes for Children Living With Cancer","recruitment_status":"","last_update_posted":"June 18, 2021","publications":[],"projects":["1U01CA246612-01"]},"NCT04089358":{"title":"Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study","recruitment_status":"","last_update_posted":"August 25, 2021","publications":[],"projects":["1U01CA246665-01"]},"NCT04941300":{"title":"ColoRectal Cancer Screening for Southern California Community Health Centers","recruitment_status":"","last_update_posted":"July 19, 2021","publications":[],"projects":["1UG3CA233314-01A1"]},"NCT04890054":{"title":"Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC","recruitment_status":"","last_update_posted":"July 15, 2021","publications":[],"projects":["1UG3CA244298-01"]},"NCT04745754":{"title":"The Engaging Primary Care in Cancer Survivorship (EPICS) Study","recruitment_status":"","last_update_posted":"August 4, 2021","publications":[],"projects":["1R01CA249419-01"]},"NCT05006482":{"title":"Geriatric Evaluation and Management With Survivorship Health Education (GEMS) for Older Survivors of Cancer","recruitment_status":"","last_update_posted":"August 31, 2021","publications":[],"projects":["1R01CA249467-01"]},"NCT04428905":{"title":"Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer","recruitment_status":"","last_update_posted":"February 16, 2021","publications":[],"projects":["1R01CA249501-01"]},"NCT04494945":{"title":"Identifying and Caring for Individuals With Inherited Cancer Syndrome","recruitment_status":"","last_update_posted":"June 2, 2021","publications":[],"projects":["1U01CA232819-01A1"]},"NCT04597359":{"title":"To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring","recruitment_status":"","last_update_posted":"September 20, 2021","publications":[],"projects":["3UG1CA189828-07S1"]},"NCT04467021":{"title":"Cancer and Blood Pressure Management, CARISMA Study","recruitment_status":"","last_update_posted":"March 5, 2021","publications":[],"projects":["3UG1CA189828-07S1"]},"NCT04438382":{"title":"Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis","recruitment_status":"","last_update_posted":"August 20, 2021","publications":[],"projects":["3UG1CA189828-07S1"]},"NCT04239573":{"title":"Comparing Two Methods to Follow Patients With Pancreatic Cysts","recruitment_status":"","last_update_posted":"August 6, 2021","publications":[],"projects":["3UG1CA189828-07S1"]},"NCT04001829":{"title":"Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer","recruitment_status":"","last_update_posted":"September 20, 2021","publications":[],"projects":["3UG1CA189828-07S1"]},"NCT03804255":{"title":"Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting","recruitment_status":"","last_update_posted":"November 3, 2020","publications":[],"projects":["3UG1CA189828-07S1"]},"NCT02352883":{"title":"MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ","recruitment_status":"","last_update_posted":"October 26, 2020","publications":[],"projects":["3UG1CA189828-07S1"]},"NCT03253848":{"title":"Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia","recruitment_status":"","last_update_posted":"March 9, 2021","publications":[],"projects":["3UG1CA189828-07S1"]},"NCT02933489":{"title":"Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts","recruitment_status":"Active, not recruiting","last_update_posted":"February 5, 2021","publications":[],"projects":["3UG1CA189828-07S1"]},"NCT03033992":{"title":"Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma","recruitment_status":"","last_update_posted":"September 16, 2021","publications":[],"projects":["2UM1CA081457-21"]},"NCT01836549":{"title":"Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors","recruitment_status":"Terminated","last_update_posted":"July 20, 2018","publications":[],"projects":["2UM1CA081457-21"]},"NCT00503724":{"title":"Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors","recruitment_status":"","last_update_posted":"March 6, 2012","publications":[],"projects":["2UM1CA081457-21"]},"NCT00357253":{"title":"Capecitabine and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Nonmetastatic Brain Stem Glioma or High-Grade Glioma","recruitment_status":"","last_update_posted":"January 10, 2013","publications":[],"projects":["2UM1CA081457-21"]},"NCT00112619":{"title":"Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors","recruitment_status":"","last_update_posted":"June 30, 2011","publications":[],"projects":["2UM1CA081457-21"]},"NCT01158300":{"title":"PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors","recruitment_status":"","last_update_posted":"May 4, 2015","publications":[],"projects":["2UM1CA081457-21"]},"NCT00572182":{"title":"MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer","recruitment_status":"","last_update_posted":"March 6, 2012","publications":[],"projects":["2UM1CA081457-21"]},"NCT00021229":{"title":"Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma","recruitment_status":"Terminated","last_update_posted":"July 31, 2014","publications":[],"projects":["2UM1CA081457-21"]},"NCT04870944":{"title":"CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma","recruitment_status":"","last_update_posted":"August 26, 2021","publications":[],"projects":["5UM1CA228823-03"]},"NCT04851119":{"title":"Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors","recruitment_status":"","last_update_posted":"September 5, 2021","publications":[],"projects":["5UM1CA228823-03"]},"NCT04158739":{"title":"Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia","recruitment_status":"","last_update_posted":"September 9, 2021","publications":[],"projects":["5UM1CA228823-03"]},"NCT01031953":{"title":"Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy","recruitment_status":"Terminated","last_update_posted":"May 9, 2017","publications":[],"projects":["3P30CA069533-22S5"]},"NCT00900055":{"title":"Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma","recruitment_status":"","last_update_posted":"July 24, 2020","publications":[],"projects":["3P30CA069533-22S5"]},"NCT01913015":{"title":"Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer","recruitment_status":"","last_update_posted":"April 28, 2017","publications":[],"projects":["3P30CA069533-22S5"]},"NCT01649505":{"title":"Fibrin Sealant in Preventing Fluid Build Up During Surgery in Patients Undergoing Breast Reconstruction","recruitment_status":"Terminated","last_update_posted":"March 15, 2013","publications":[],"projects":["3P30CA069533-22S5"]},"NCT01005914":{"title":"Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","recruitment_status":"Terminated","last_update_posted":"March 4, 2015","publications":[],"projects":["3P30CA069533-22S5"]},"NCT00900302":{"title":"OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer","recruitment_status":"","last_update_posted":"February 10, 2016","publications":[],"projects":["3P30CA069533-22S5"]},"NCT00899795":{"title":"Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers","recruitment_status":"","last_update_posted":"December 4, 2017","publications":[],"projects":["3P30CA069533-22S5"]},"NCT03677531":{"title":"Video Distraction to Decrease Use of Sedation in Pediatric Participants During Radiation Therapy","recruitment_status":"","last_update_posted":"May 4, 2020","publications":[],"projects":["3P30CA069533-22S5"]},"NCT03479268":{"title":"Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma","recruitment_status":"","last_update_posted":"July 7, 2021","publications":[],"projects":["3P30CA069533-22S5"]},"NCT03261180":{"title":"Nestle Impact Advanced Recovery in Improving Surgery Recovery in Patients With Head and Neck Cancer","recruitment_status":"","last_update_posted":"February 25, 2020","publications":[],"projects":["3P30CA069533-22S5"]},"NCT00567229":{"title":"Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma","recruitment_status":"Terminated","last_update_posted":"November 20, 2015","publications":[],"projects":["3P30CA008748-54S3"]},"NCT00550628":{"title":"Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer","recruitment_status":"","last_update_posted":"December 23, 2015","publications":[],"projects":["3P30CA008748-54S3"]},"NCT00541034":{"title":"Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia","recruitment_status":"Completed","last_update_posted":"August 11, 2017","publications":[],"projects":["3P30CA008748-54S3"]},"NCT00519974":{"title":"Factors Affecting Decisions About Breast Reconstruction After Mastectomy in Black and Latina Women","recruitment_status":"","last_update_posted":"October 1, 2015","publications":[],"projects":["3P30CA008748-54S3"]},"NCT00514254":{"title":"Risk Factors for Endometrial Cancer in Black Women","recruitment_status":"","last_update_posted":"August 10, 2021","publications":[],"projects":["3P30CA008748-54S3"]},"NCT00483678":{"title":"Couples Therapy to Enhance Intimacy Between Patients With Advanced or Recurrent Prostate Cancer and Their Partners","recruitment_status":"","last_update_posted":"March 6, 2018","publications":[],"projects":["3P30CA008748-54S3"]},"NCT00471679":{"title":"Ethanol-Lock Treatment in Preventing Central Venous Catheter Infections in Patients With High-Risk Neuroblastoma","recruitment_status":"","last_update_posted":"March 5, 2013","publications":[],"projects":["3P30CA008748-54S3"]},"NCT00471601":{"title":"Development of a Questionnaire to Evaluate Patient Expectations for Breast Reconstruction in Women With Breast Cancer or Other Conditions","recruitment_status":"","last_update_posted":"October 5, 2020","publications":[],"projects":["3P30CA008748-54S3"]},"NCT00470574":{"title":"Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer","recruitment_status":"Completed","last_update_posted":"November 18, 2020","publications":[],"projects":["3P30CA008748-54S3"]},"NCT00462982":{"title":"Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma","recruitment_status":"Completed","last_update_posted":"December 30, 2015","publications":[],"projects":["3P30CA008748-54S3"]},"NCT01418495":{"title":"Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma","recruitment_status":"","last_update_posted":"October 1, 2019","publications":[],"projects":["3P30CA016520-44S5","3P30CA016520-44S6"]},"NCT00679094":{"title":"Bowman-Birk Inhibitor Concentrate in Healthy Men","recruitment_status":"","last_update_posted":"December 29, 2016","publications":[],"projects":["3P30CA016520-44S5","3P30CA016520-44S6"]},"NCT01873833":{"title":"Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer","recruitment_status":"","last_update_posted":"August 26, 2021","publications":[],"projects":["3P30CA014089-45S6"]},"NCT04981834":{"title":"Robot-Assisted Radical Prostatectomy With or Without Vesicopexy in Patients With Prostate Cancer","recruitment_status":"","last_update_posted":"July 29, 2021","publications":[],"projects":["3P30CA014089-45S6"]},"NCT04941430":{"title":"7T MRI Scan for the Early Detection of Melanoma Brain Metastases","recruitment_status":"","last_update_posted":"June 28, 2021","publications":[],"projects":["3P30CA014089-45S6"]},"NCT04927559":{"title":"Health Literacy in Understanding Radiation Therapy Information in Patients Undergoing Definitive Radiation Therapy","recruitment_status":"","last_update_posted":"June 16, 2021","publications":[],"projects":["3P30CA014089-45S6"]},"NCT04832763":{"title":"Medical and Psychosocial Issues in Adolescents and Young Adults With Colorectal Cancer","recruitment_status":"","last_update_posted":"April 6, 2021","publications":[],"projects":["3P30CA014089-45S6"]},"NCT04830735":{"title":"Dasatinib for the Treatment of Moderate and Severe COVID-19","recruitment_status":"","last_update_posted":"June 10, 2021","publications":[],"projects":["3P30CA014089-45S6"]},"NCT04752267":{"title":"18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases","recruitment_status":"","last_update_posted":"March 17, 2021","publications":[],"projects":["3P30CA014089-45S6"]},"NCT04387084":{"title":"Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy","recruitment_status":"","last_update_posted":"April 5, 2021","publications":[],"projects":["3P30CA014089-45S6"]},"NCT04387071":{"title":"CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma","recruitment_status":"","last_update_posted":"April 5, 2021","publications":[],"projects":["3P30CA014089-45S6"]},"NCT04373044":{"title":"Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19","recruitment_status":"","last_update_posted":"May 26, 2021","publications":[],"projects":["3P30CA014089-45S6"]},"NCT02189486":{"title":"Prostate Cancer Upgrading Reference Set","recruitment_status":"","last_update_posted":"June 30, 2021","publications":[],"projects":["3P30CA054174-25S2","3P30CA054174-25S1"]},"NCT00055822":{"title":"Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer","recruitment_status":"","last_update_posted":"July 4, 2012","publications":[],"projects":["3P30CA054174-25S2","3P30CA054174-25S1"]},"NCT00003709":{"title":"Chemotherapy in Treating Patients With Advanced Solid Tumors","recruitment_status":"","last_update_posted":"August 9, 2012","publications":[],"projects":["3P30CA054174-25S2","3P30CA054174-25S1"]},"NCT00003760":{"title":"Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer","recruitment_status":"","last_update_posted":"August 9, 2012","publications":[],"projects":["3P30CA054174-25S2","3P30CA054174-25S1"]},"NCT00003708":{"title":"Chemotherapy in Treating Patients With Advanced Solid Tumors","recruitment_status":"","last_update_posted":"August 9, 2012","publications":[],"projects":["3P30CA054174-25S2","3P30CA054174-25S1"]},"NCT00003710":{"title":"Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors","recruitment_status":"","last_update_posted":"August 9, 2012","publications":[],"projects":["3P30CA054174-25S2","3P30CA054174-25S1"]},"NCT00003706":{"title":"LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function","recruitment_status":"","last_update_posted":"June 28, 2012","publications":[],"projects":["3P30CA054174-25S2","3P30CA054174-25S1"]},"NCT00003712":{"title":"CCI-779 in Treating Patients With Advanced Solid Tumors","recruitment_status":"","last_update_posted":"August 9, 2012","publications":[],"projects":["3P30CA054174-25S2","3P30CA054174-25S1"]},"NCT00003707":{"title":"Combination Chemotherapy in Treating Patients With Advanced Cancer","recruitment_status":"","last_update_posted":"June 28, 2012","publications":[],"projects":["3P30CA054174-25S2","3P30CA054174-25S1"]},"NCT00003721":{"title":"Chemotherapy in Treating Patients With Advanced Solid Tumors","recruitment_status":"","last_update_posted":"June 29, 2012","publications":[],"projects":["3P30CA054174-25S2","3P30CA054174-25S1"]},"NCT00064272":{"title":"UMCCOP 02-01 Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer","recruitment_status":"","last_update_posted":"October 21, 2016","publications":[],"projects":["3P30CA046592-31S8","3P30CA046592-31S4"]},"NCT00098969":{"title":"UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants","recruitment_status":"","last_update_posted":"December 17, 2012","publications":[],"projects":["3P30CA046592-31S8","3P30CA046592-31S4"]},"NCT00967824":{"title":"Tamoxifen Citrate Decision Aids for Women at Increased Risk of Breast Cancer","recruitment_status":"","last_update_posted":"March 24, 2011","publications":[],"projects":["3P30CA046592-31S8","3P30CA046592-31S4"]},"NCT00955188":{"title":"Computer-Based Tailored or Standard Information for Colorectal Cancer Screening","recruitment_status":"","last_update_posted":"December 21, 2012","publications":[],"projects":["3P30CA046592-31S8","3P30CA046592-31S4"]},"NCT00900094":{"title":"UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer","recruitment_status":"","last_update_posted":"February 7, 2012","publications":[],"projects":["3P30CA046592-31S8","3P30CA046592-31S4"]},"NCT00003076":{"title":"Eflornithine to Prevent Cancer in Patients With Barrett&apos;s Esophagus","recruitment_status":"","last_update_posted":"December 19, 2012","publications":[],"projects":["3P30CA046592-31S8","3P30CA046592-31S4"]},"NCT00005598":{"title":"Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome","recruitment_status":"","last_update_posted":"December 21, 2012","publications":[],"projects":["3P30CA046592-31S8","3P30CA046592-31S4"]},"NCT00003598":{"title":"UMCC 9609 Tretinoin in Preventing Cancer of the Cervix in Patients With Cervical Neoplasia","recruitment_status":"","last_update_posted":"September 22, 2010","publications":[],"projects":["3P30CA046592-31S8","3P30CA046592-31S4"]},"NCT00027495":{"title":"Curcumin for the Prevention of Colon Cancer","recruitment_status":"","last_update_posted":"December 21, 2012","publications":[],"projects":["3P30CA046592-31S8","3P30CA046592-31S4"]},"NCT02007200":{"title":"Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery","recruitment_status":"Completed","last_update_posted":"October 24, 2016","publications":[],"projects":["3P30CA046592-31S8","3P30CA046592-31S4"]},"NCT01700959":{"title":"Melatonin Intervention For Neurocognitive Deficits in the St. Jude Lifetime Cohort","recruitment_status":"Completed","last_update_posted":"June 28, 2018","publications":[],"projects":["3P30CA021765-41S3"]},"NCT00004006":{"title":"Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma","recruitment_status":"","last_update_posted":"October 4, 2011","publications":[],"projects":["3P30CA021765-41S3"]},"NCT00004005":{"title":"Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin","recruitment_status":"","last_update_posted":"April 26, 2017","publications":[],"projects":["3P30CA021765-41S3"]},"NCT00137111":{"title":"Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia","recruitment_status":"Completed","last_update_posted":"September 11, 2020","publications":[],"projects":["3P30CA021765-41S3"]},"NCT00576472":{"title":"Learning Impairments Among Survivors of Childhood Cancer","recruitment_status":"Completed","last_update_posted":"May 30, 2017","publications":[],"projects":["3P30CA021765-41S3"]},"NCT00002794":{"title":"Carboplatin Plus Vincristine in Treating Children With Retinoblastoma","recruitment_status":"","last_update_posted":"October 4, 2011","publications":[],"projects":["3P30CA021765-41S3"]},"NCT00004068":{"title":"Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor","recruitment_status":"","last_update_posted":"October 4, 2011","publications":[],"projects":["3P30CA021765-41S3"]},"NCT00002748":{"title":"Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma","recruitment_status":"","last_update_posted":"October 4, 2011","publications":[],"projects":["3P30CA021765-41S3"]},"NCT00101205":{"title":"Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma","recruitment_status":"","last_update_posted":"February 24, 2014","publications":[],"projects":["3P30CA021765-41S3"]},"NCT04662645":{"title":"Embedded Palliative Care in Managing Symptoms in Participants With Recurrent Stage III-IV Thoracic Malignancies and Their Caregivers","recruitment_status":"","last_update_posted":"December 10, 2020","publications":[],"projects":["3P30CA016058-44S3"]},"NCT04602026":{"title":"Re-Defining Frailty and Improving Outcomes Through Prehabilitation in Patients With Pancreatic, Liver, or Gastric Cancer, The RIOT Trial","recruitment_status":"","last_update_posted":"October 27, 2020","publications":[],"projects":["3P30CA016058-44S3"]},"NCT04329962":{"title":"Metabolism and Absorption of Anthocyanins From Extract and Whole Blueberry Powder Confections in Healthy Adults","recruitment_status":"","last_update_posted":"April 1, 2020","publications":[],"projects":["3P30CA016058-44S3"]},"NCT04269837":{"title":"Sexual Health Counseling Intervention During Radiation Therapy in Improving Quality of Life for Women With Gynecologic Cancer","recruitment_status":"","last_update_posted":"December 8, 2020","publications":[],"projects":["3P30CA016058-44S3"]},"NCT04229381":{"title":"Resiliency Among Older Adults Receiving Lung Cancer Treatment","recruitment_status":"","last_update_posted":"January 18, 2020","publications":[],"projects":["3P30CA016058-44S3"]},"NCT04220684":{"title":"Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","recruitment_status":"","last_update_posted":"June 4, 2020","publications":[],"projects":["3P30CA016058-44S3"]},"NCT04205071":{"title":"Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer","recruitment_status":"","last_update_posted":"January 19, 2021","publications":[],"projects":["3P30CA016058-44S3"]},"NCT04164069":{"title":"Dasatinib in Preventing Oxaliplatin-Induced Peripheral Neuropathy in Patients With Colorectal Cancer Receiving FOLFOX and Bevacizumab","recruitment_status":"","last_update_posted":"July 8, 2021","publications":[],"projects":["3P30CA016058-44S3"]},"NCT04120454":{"title":"Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer","recruitment_status":"","last_update_posted":"October 9, 2020","publications":[],"projects":["3P30CA016058-44S3"]},"NCT04115163":{"title":"Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer","recruitment_status":"","last_update_posted":"September 17, 2020","publications":[],"projects":["3P30CA016058-44S3"]},"NCT04162873":{"title":"Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer","recruitment_status":"","last_update_posted":"September 8, 2021","publications":[],"projects":["3P30CA042014-31S5"]},"NCT04106856":{"title":"Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER)","recruitment_status":"","last_update_posted":"July 16, 2021","publications":[],"projects":["3P30CA042014-31S5"]},"NCT03987217":{"title":"Resistance Training +/- Creatine for Metastatic Prostate Cancer Patients","recruitment_status":"","last_update_posted":"January 13, 2021","publications":[],"projects":["3P30CA042014-31S5"]},"NCT03972943":{"title":"CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia","recruitment_status":"","last_update_posted":"April 22, 2021","publications":[],"projects":["3P30CA042014-31S5"]},"NCT00335491":{"title":"Exercise in Improving Mobility and Reducing Fatigue and/or Weakness in Older Cancer Survivors","recruitment_status":"","last_update_posted":"September 30, 2011","publications":[],"projects":["3P30CA042014-31S5"]},"NCT00026468":{"title":"Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis","recruitment_status":"","last_update_posted":"July 24, 2013","publications":[],"projects":["3P30CA042014-31S5"]},"NCT02337517":{"title":"Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease","recruitment_status":"Terminated","last_update_posted":"July 19, 2021","publications":[],"projects":["3P30CA042014-31S5"]},"NCT02159755":{"title":"Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma","recruitment_status":"","last_update_posted":"May 21, 2021","publications":[],"projects":["3P30CA013696-45S1"]},"NCT00233935":{"title":"Defined Green Tea Catechin Extract in Preventing Esophageal Cancer in Patients With Barrett&apos;s Esophagus","recruitment_status":"","last_update_posted":"September 11, 2014","publications":[],"projects":["3P30CA013696-45S1"]},"NCT04109924":{"title":"TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study","recruitment_status":"","last_update_posted":"July 23, 2021","publications":[],"projects":["3P30CA016056-43S5"]},"NCT00957424":{"title":"Acceptability of Less Harmful Alternatives to Cigarettes","recruitment_status":"Completed","last_update_posted":"February 7, 2017","publications":[],"projects":["3P30CA016056-43S5"]},"NCT00849186":{"title":"Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer","recruitment_status":"Completed","last_update_posted":"February 6, 2015","publications":[],"projects":["3P30CA016056-43S5"]},"NCT00736164":{"title":"Selenomethionine in Treating Patients Undergoing Surgery or Internal Radiation Therapy for Stage I or Stage II Prostate Cancer","recruitment_status":"","last_update_posted":"February 6, 2012","publications":[],"projects":["3P30CA016056-43S5"]},"NCT01892930":{"title":"Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery","recruitment_status":"","last_update_posted":"February 10, 2017","publications":[],"projects":["3P30CA016056-43S5"]},"NCT00690924":{"title":"Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer","recruitment_status":"Completed","last_update_posted":"June 4, 2018","publications":[],"projects":["3P30CA016056-43S5"]},"NCT01769885":{"title":"Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer","recruitment_status":"","last_update_posted":"April 11, 2017","publications":[],"projects":["3P30CA016056-43S5"]},"NCT00560495":{"title":"Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer","recruitment_status":"","last_update_posted":"February 10, 2012","publications":[],"projects":["3P30CA016056-43S5"]},"NCT01555268":{"title":"Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia","recruitment_status":"","last_update_posted":"February 15, 2017","publications":[],"projects":["3P30CA016056-43S5"]},"NCT00217516":{"title":"Selenium in Treating Patients Who Are Undergoing Brachytherapy for Stage I or Stage II Prostate Cancer","recruitment_status":"","last_update_posted":"February 9, 2012","publications":[],"projects":["3P30CA016056-43S5"]},"NCT00095927":{"title":"Randomized Amifostine For SCCHN","recruitment_status":"","last_update_posted":"January 4, 2017","publications":[],"projects":["3P30CA006516-55S9"]},"NCT00095901":{"title":"Capecitabine For Nasopharyngeal Cancer","recruitment_status":"","last_update_posted":"March 29, 2018","publications":[],"projects":["3P30CA006516-55S9"]},"NCT00084838":{"title":"Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT","recruitment_status":"Completed","last_update_posted":"December 24, 2015","publications":[],"projects":["3P30CA006516-55S9"]},"NCT00069940":{"title":"Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor","recruitment_status":"","last_update_posted":"December 28, 2010","publications":[],"projects":["3P30CA006516-55S9"]},"NCT03029325":{"title":"Molecular and Genetic Analysis of Lung Cancer","recruitment_status":"","last_update_posted":"March 4, 2021","publications":[],"projects":["3P30CA006516-55S9"]},"NCT00429910":{"title":"Natural History Study of Patients With Chronic Myelogenous Leukemia","recruitment_status":"","last_update_posted":"January 2, 2017","publications":[],"projects":["3P30CA006516-55S9"]},"NCT00357500":{"title":"Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer","recruitment_status":"Completed","last_update_posted":"October 1, 2014","publications":[],"projects":["3P30CA006516-55S9"]},"NCT00101075":{"title":"Title XELOX FOR SALIVARY GLAND CANCERS","recruitment_status":"","last_update_posted":"February 27, 2017","publications":[],"projects":["3P30CA006516-55S9"]},"NCT00098865":{"title":"Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma","recruitment_status":"Completed","last_update_posted":"October 7, 2014","publications":[],"projects":["3P30CA006516-55S9"]},"NCT00095875":{"title":"Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)","recruitment_status":"Completed","last_update_posted":"November 19, 2013","publications":[],"projects":["3P30CA006516-55S9"]}}